Naringing reverses HIV-1 protease inhibitors-associated pancreatic beta-cell dysfunction in vitro. by Nzuza, Sanelisiwe.









    
NARINGING REVERSES HIV-1 PROTEASE INHIBITORS-




                                                      By 
                                      SANELISIWE NZUZA 
                                               207508019 
                               B. Sc. B. Med. Sc. (Hons) (UKZN)  
         Submitted in fulfilment of the requirements for the degree  
                                                       of 
          MASTER OF MEDICAL SCIENCE IN PHARMACOLOGY  
 
Discipline of Pharmaceutical Science, School of Health Sciences, Collage of Health Sciences     










                                                ACKNOWLEDGEMENTS 
My parents  
Lord said “he has the plans for us, not to harm us but to prosper us. With you everything is 
possible. Thank you for the words of encouragement. 
My beloved mom Thembelihle Sandra Nzuza, Thabisile Nene, Ndumiso Nzuza and Phumlani 
Nzuza without you I would not be here. Thank you so much for your support, encouragement, 
motivation and always having a faith in me.  
Dr. P. M. O. Owira 
Approachable father, I would like to thank you for giving me the greatest opportunity of being 
the part of your department and experiencing Pharmacology in your vision. Also, the endless 
love, kindness and advises that you give me throughout my research.  
Dr. D. Onyango 
I am grateful for all that you have done to assist me in writing my thesis, encouragement, 
advises and the kindness you showed me through my research.  
Ms Kogi Moodley 
Many thanks for technical assistance in the Department of Physiology.  
Scholarship    
The UKZN College of Health Science scholarship, thank you for finding this work.  
 
 




                                                             PRESENTATIONS 
S. Nzuza and P. M. O Owira 
17th World Congress Pharmacology of Basic and Clinical Pharmacology (July 2014) Cape 
Town  
UKZN College of Health Sciences research symposium (September 2014), Durban, South 
Africa  
“Glibenclamide reverses HIV-1 Protease inhibitors-induced β-cell dysfunction in RIN-5F 
cells by relieving oxidative stress”. Journal: Diabetes, DB15-0048, 13-Jan-2015, Manuscript 
















                                                LIST OF ABBREVIATIONS  
µg/Dl Micrograms per decilitre 
µl Microliter 
µM Micromolar 
•OH Hydroxyl radical 
ADP Adenosine Diphosphate 
AgRP Agoutigene-Related Protein 
AIDS       Acquired immunodeficiency syndrome 
AIF Apoptosis inducing factor 
AMPK Adenosine Monophosphate-activated Protein Kinase 
AMPK Adenosine Monophosphate-activated Protein Kinase 
ANOVA      Analysis of variance 
Apaf-1                   Apoptotic protease activating factor-1 
ART Antiretroviral Therapy 
ARVs   Anti-retro viral drugs 
ASK-1 Apoptosis Signal-regulating Kinase 1 
ATP Adenosine Triphosphate 
Bax Bcl-2 associated X protein 
Bcl-2                       B-cell CLL/Lymphoma 2 
BHT Butylated hydroxytoluene 
BMI Body Mass Index 
BP Blood pressure 
BSA Bovine serum albumin 
Ca2+ Calcium ion 




CaCl2 Calcium chloride 
CAD Caspase activated DNase 
cAMP cyclic Adenosine Monophosphate 
CARDs Caspase recruitment domains 
CART Amphetamine-Regulated Transcript 
CCM Complete culture media 
CCR5 Co-receptors Chemokine Receptors (R5-tropic strains) 
CH2 Methylene-carbon 
Cm Centimetre 
CO2   Carbon dioxide 
CRABP-1 Cytoplasmic retinoic acid binding protein type 1 
CXCR4 C-X-C chemokine receptor type 4 
CYP3A4 Cytochrome P450 3A4 
CYP450 Cytochrome P450 
DEDs Death Effector Domains 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic Acid 
Ds Double stranded 
EDTA Ethylenediaminetetraacetic acid 
eIF4F Eukaryotic translation initiation factor 4F 
eIF4G Eukaryotic translation initiation factor 4 gamma 
ELISA Enzyme-linked immunosorbent assay 
ERKs Extracellular signal-related kinases 
ETC Electron transport chain 
FADH2 Flavin Adenine Dinucleotide 




FBS Fetal bovine serum 
Fe2+ Ferrous 
g    Gravitational force 
GLUT-4 Glucose transporter isoform 4 
GPx Glutathione peroxidise 
GR Glutathione reductase 
GSH          Glutathione 





H2O2 Hydrogen peroxide 
H3PO4 Phosphoric acid 
HAART Highly Active Anti-Retroviral Therapy 
HCl Hydrochloric acid 
HIV Human immunodeficiency virus 
IAP Inhibitor of apoptosis protein 
IL-6 Interleukin 6 
IRS Insulin Receptor Substrate 
JAK/STAT3 Janus kinase signal transducer and activator of transcription 3 
JNK c-Jun N-terminal Kinases 
KATP ATP-sensitive potassium 
KCl Potassium chloride 
KRBB Krebs Ringer Bicarbonate Buffer 




LRP LDL receptor-related protein 
MAPK Mitogen-activated Protein Kinase 
MDA      Malondialdehyde 
mg/dL Milligrams per decilitre 
Mg2+ Magnesium 





MnSOD Manganese Superoxide DismutasE 
NaCl Sodium Chloride 
NADH  Nicotinamide Adenine Dinucleotide 
NaH2PO4 Monosodium phosphate 
NaHCO3 Sodium bicarbonate 
NCEP ATP III National Cholesterol Education Program Adult Treatment Panel 
NNRTIs Non-Nucleoside Reverse Transcriptase Inhibitors 
NPY Neuropeptide Y 
NRTIs Nucleoside Reverse Transcriptase Inhibitors 
O2 Oxygen 
O2•–                   Superoxide 
P Statistical probability 
PARP-1               Poly (ADP-ribose) polymerase-1 
PBS Phosphate buffer saline 
PI3K Phosphatidylinositol 3-kinase 




PIs Protein Inhibitors 
POMC Pro-opiomelanocortin 
PPAR-γ               Peroxisomal Proliferator–Activated Receptor γ 
PUFA Polyunsaturated fatty acid 
RA Retinoic Acid 
RFU Relative Fluorescence Units 
RLU Relative light unit 
RNA Ribonucleic acid 
ROS   Reactive oxygen species 
Rpm Revolutions per minute 
RT Room temperature 
RXR Retinoic X receptor 
RXR Retinoic X receptor 
SEM Standard error of the mean 
Smac/DIABLO Second mitochondria-derived activator of caspases/DIABLO 
SNPs Single Nucleotide Polymorphisms 
SOC3 Suppressor of Cytokine signaling 3 
SOD Superoxide dismutase 
SREBP-1c             Sterol Regulatory Element Binding Protein-1c 
ssRNA single-stranded RNA 
SUR1 Sulfonylurea receptor 1 
TBA Thiobarbituric acid 
TBARS Thiobarbituric acid reactive substances 
TCA Tricarboxylic Acid 
TMB Tetramethylbenzidine 




TNF Tumor Necrosis Factor 
TNF-α Tumor Necrosis Factor-alpha 
UCP2 Uncoupling Protein 2 
UNAIDS United Nations Programme on HIV/AIDS 
VLDL   Very Low Density Lipoprotein 
WHO World Health Organisation 
WST Water-Solution tretrazolium 
                                                  
 




                                                













                                               LIST OF FIGURES 
Chapter one 
Figure 1 Illustration of Protease inhibitors- mediated with metabolic syndrome (Flint, Noor 
et al. 2009) 
 
11 




Figure 3 The structure of Naringin (4′, 5, 7-trihydroxy flavonone 7-rhamnoglucoside)  (Cui, 




Figure 4 Principle of the ATP assay for the quantification of cellular ATP. 25 
Figure 5  The reaction of malondialdehyde with thiobarbituric acid (prepared by author). 26 
Figure 6 The principle of determination of SOD activity by SOD assay (prepared by author).       27 
Figure 7 The principle of the GSH-Glo™ Glutatione assay (prepared by author). 28 
Figure 8 The principle for the detection of caspase-9 activity (prepared by author). 29 
Figure 9  Principle for the detection of caspase-3 activity (prepared by author). 30 
 
Chapter three 
Figure 10 Glucose-induced insulin secretion in cells that were treated with (A) PIs and/or (B) 
glibenclamide.  
33 
Figure 11 ATP productions after cells were treated with (A) PIs and/or (B) glibenclamide at 
different concentrations of glucose. 
34 
Figure 12 Linear regression analysis of concentration-depend inhibition of insulin secretion 
in RIN-5F cultured cells.                                                                                        
35 




Figure 13  TBARS assay measured as MDA concentrations after cells were treated with (A) 
PIs and/or (B) glibenclamide at different concentrations of glucose. 
36 
Figure 14 SOD activity after cells were exposed with (A) PIs and/or (B) glibenclamide at 
different concentrations of glucose 
37 
Figure 15 Glutathione levels after cells were exposed with (A) PIs and/or (B) glibenclamide 
at different concentrations of glucose. 
38 
Figure 16 A dose-dependent increase insulin secretion in cells after naringin treatment.     41 
Figure 17 Malondialdehyde (lipid peroxidation) levels in RIN-5F cells treated with PIs and/ 
or naringin.  
42 
Figure 18 SOD activity after cells were exposed to PIs and/ or naringin for 24 hours 43 
Figure 19 Glutathione levels after cells were exposed to PIs and/naringin for 24 hours.  44 
Figure 20 ATP levels after cells were exposed to PIs and/ or naringin 45 
                 
 









                                                            




                                                       LIST OF TABLES 
Table 1 Antiretroviral drugs for treatment of HIV infection 4 
Table 2 Caspase-3 activity in RIN-5F cells (*p< 0.05).  39 
Table 3 Caspase-9 activity in RIN-5F cells (*p< 0.05). 40 




















                                                               ABSTRACT  
Introduction: Chronic exposure to HIV-1 Protease Inhibitors (PIs) has been associated with 
pancreatic β-cell dysfunction and impairment of insulin secretion. PIs have been suggested to 
induce β-cell dysfunction through increasing oxidative stress leading to impaired insulin 
secretion. The study investigated whether naringin, a naturally occurring antioxidant, could 
reverse PIs-induced β-cell dysfunction by reducing oxidative stress. 
Methods: The RIN-5F cells were cultured in RPM1-1640 medium, allowed to grow to 80% 
confluence, exposed to different concentrations of PIs [nelfinavir (1-10 µM), saqanavir (1-10 
µM) and atazanavir (5-20 µM)] in the presence of 11 mM glucose for 24 hr then subjected to 
insulin ELISA assay to assess dose-dependent suppression of insulin of secretion by PIs. To 
determine glucose-induced insulin secretion, the cells were exposed to nelfinavir (10 µM), 
saquinavir (10 µM), atazanavir (20 µM) 24 hr with or without glibenclamide (10 µM) in the 
presence of varying glucose concentrations (11-25 mM) then harvested and subjected to 
biochemical assays for the measurement of insulin levels, lipid peroxidation, ATP generation, 
Glutathione levels (GSH), Superoxide dismutase (SOD) and caspase-3 and -9 activities.  
Cells were further exposed to naringin (0-50 µM) in the presence of 11 mM glucose for 24 hr 
then subjected to insulin ELISA for insulin secretion determination. To investigate the role of 
PIs relative to naringin on RIN-5F cells, the cells were exposed to nelfinavir (10 µM), 
saquinavir (10 µM) and atazanavir (20 µM) with or without naringin (10 µM) also in the 
presence of 11 mM for 24 hr and similarly subjected to biochemical assays.  
Results: Linear regression analysis showed significant decrease in insulin levels in response 
to nelfinavir, saqunavir and atazanavir (r2= 0.86, 0.76, 0.95, respectively) in a dose-dependent 
manner. PIs significantly (p < 0.05) reduced insulin secretion and ATP production, increased 
lipid peroxidation, SOD and caspase-3 and -9 activities and also reduced GSH in a glucose-




dependent manner. These effects were reversed by glibenclamide. Naringin (0-50 µM) caused 
dose-dependent increased in insulin secretion and also reduced lipid peroxidation, SOD, 
caspase-3 and -9 activities, increased GSH and ATP levels in cells that were exposed to PIs.    
Conclusion: PIs induced β-cell dysfunction and impairment of insulin secretion by increasing 
oxidative stress and ATP depletion. Naringin ameliorated PIs-induced impairment of β-cell 
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                                                                 CHAPTER ONE 
1. Introduction 
1.1. HIV epidemiology 
Human immunodeficiency virus-1 (HIV-1) remains a global health problem even after 25 years 
since the epidemic began (Maartens et al., 2014). According to the current statistics, 
approximately 35.3 million people are living with HIV and 1.6 million died of human 
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related illnesses 
globally (UNAIDS., 2013). HIV prevalence appears to be higher in individuals residing in low 
income countries (95%) compared to individuals residing in high income countries (UNAIDS., 
2013). Sub-Saharan Africa has the most serious HIV-1 epidemic worldwide with 
approximately 25 million individuals living with HIV, which accounts for 70% of the 
worldwide total population (Beyrer and Abdool Karim, 2013). In these countries, HIV-1 
contagion has remarkable consequences on civilization, affecting life expectancy occupants, 
decelerating economic growth and increasing poverty (UNAIDS., 2013)  
South Africa has a highest incidence of HIV globally, with 5.6 million individuals currently 
living with HIV-1 (Bekker et al., 2014). According to UNAIDS, the total number of South 
Africans infected with HIV has increased from 4.1 million in 2001 to 5.7 million in 2010 
(Bekker et al., 2014). The HIV-1 prevalence appears to be higher in females (45%) between 
the ages of 15-49 years, and 20% being children under the age of 15 years (Bekker et al., 2014). 
According to World Health Organisation, this is partly due to the fact that most individuals are 
ignorant of their status (Bekker et al., 2014; Castilla et al., 2005).  
 
 




1.2 HIV treatment  
The introduction of antiretroviral drugs (ARVs) in 1996 has greatly improved the natural 
course of the disease in the affected individuals (Anuurad et al., 2010). They reduce viral 
replication, increasing CD4+ count, thus decreasing the risk of contracting opportunistic 
infections that frequently lead to death (Kis et al., 2010; Rudich et al., 2001). There are six 
different classes of ARVs permitted by World Health Organisation (Apostolova et al., 2011; 
Dau and Holodniy, 2008).  They include 1) entry inhibitors which bind to the host CCR5 
receptors, therefore preventing interaction of viral gp120 and host CCR5 which is necessary 
for the entry into the host cell;  2) Fusion inhibitors which prevent entry of viral nucleic acid  
into the host CD4 cell (Apostolova et al., 2011; Dau and Holodniy, 2008; Loonam and Mullen, 
2012); 3) Nucleotide Reverse Transcriptase Inhibitors (NRTIs) which are false nucleoside 
analogues, which act as substrates incorporated into the active site of HIV reverse transcriptase 
leading to termination of chain elongation (Apostolova et al., 2011; Dau and Holodniy, 2008; 
Kis et al., 2010); 4) Non-nucleosides Reverse Transcriptase Inhibitors (NNRTIs) that bind 
allosterically to a hydrophobic pocket situated at 10 amino acid residues away from catalytic 
site of the enzyme (Apostolova et al., 2011; Dau and Holodniy, 2008; Loonam and Mullen, 
2012). Therefore, the binding of NNRTI induces conformation changes at Tyr-181 and Tyr-
188 residues, affecting active site of  reverse transcriptase and thereby preventing HIV-1 
replication; 5) Integrase Inhibitors (IIs) block the integration of viral cDNA to the host genome 
(Dau and Holodniy, 2008; Kis et al., 2010). It binds to the active site of Mg2+ within HIV-1 
integrase, thus blocking active site from binding to target DNA strand; 6) protease inhibitors 
(PIs) bind to the substrate side of the enzyme, imitating tetrahedral intermediates of its substrate 
(Dau and Holodniy, 2008; Loonam and Mullen, 2012). This leads to inhibition of HIV-1 
proteases and subsequently production of immature proteins and non-infectious virons 
(Apostolova et al., 2011; Kis et al., 2010; Loonam and Mullen, 2012). 




Table 1: Antiretroviral drugs for treatment of HIV infection (Dau and Holodniy, 2008). 
Drugs class Available Antiretroviral Agents 
Entry inhibitor Maraviroc (MAC) 
Fusion inhibitor Enfuvirtide (T-20) 
Integrase inhibitor Raltegravir (RAL) 








Zidovudine (AZT or ZDV) 








Zidovudine (AZT or ZDV) 









The current guidelines for HIV management constitute Highly Active Antiretroviral Therapy 
(HAART) include the use of three different classes of antiretroviral drugs; 2 NRTIs and 1 
NNRTIs or 1 PIs (Feeney and Mallon, 2011; Loonam and Mullen, 2012). The use of the fixed 




dose antiretroviral therapy has also been introduced (April 2013) by the Department of Health 
in South Africa in order to improve compliance of those being treated with the antiretroviral 
agents (Clinicians Society, 2013; Gandhi and Gandhi, 2014).   
While improving the clinical course of HIV positive patients, it has become apparent that the 
long-term use of HAART especially those containing PIs in the management of HIV often 
results in the development of symptoms of metabolic syndrome such as lipodystrophy, 
dyslipidemia, insulin resistance (Heath et al., 2002; Souza et al., 2013; Vu et al., 2013; Woerle 
et al., 2003). Approximately 60% of HIV patients treated with PI-containing therapy developed 
either glucose intolerance or insulin resistance and 83% developed lipodystrophy (James et al., 
2002; Rudich et al., 2001; Saves et al., 2002; Woerle et al., 2003). 
 
Metabolic syndrome has been documented as a multifactorial risk factor of cardiovascular 
disorder by U.S. National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) 
III report and type 2 diabetes (Barbaro, 2006; Cahn et al., 2010). The NCEP ATP III identifies 
metabolic syndrome at parametric risk factors viz:- (a) abdominal obesity, assessed as waist 
circumference > 102 cm (males) and 88 cm (females); (b) fasting glucose > 100 ng/dl (c)  blood 
pressure (BP) ≥ 130/85 mmHg; (d) HDL-cholesterol < 40 mg/dL (males) and < 50 mg/dL 
(females) (e) triglycerides > 150 mg/dl and insulin resistance (Alberti et al., 2005; Samaras et 
al., 2009). Early diagnosis could prevent development of type 2 and cardiovascular diseases 
(Alberti et al., 2005; Gayoso-Diz et al., 2013; Samaras et al., 2007).   
 
The risk factors of metabolic syndrome include genetic factors such as polymorphism or 
mutation of peroxisome-proliferator-activated receptor gamma 2 gene, chromosome 10p 
(Rankinen et al., 2006), melanocortin-4 receptor gene, beta-adrenergic receptors, Tumor 
Necrosis Factor (TNF), Neuropeptide Y (NPY) (Yeo et al., 1998), Pro-opiomelanocortin 




(POMC) (Krude et al., 1998), leptin and leptin receptor (Montague et al., 1997), obesity, 
physical inactivity and smoking.  These risk factors have been suggested to induce insulin 
resistance, hyperinsulinemia, endothelial dysfunction, inflammation cardiovascular disorders 
(Waters and Nelson, 2007)  
 




Lipodystrophy includes loss of peripheral subcutaneous fat (lipoatrophy) and central fat 
accumulation (lipohypertrophy), which may occur separately or exist in both forms in a single 
patient (Guaraldi et al., 2005; Mencarelli et al., 2012; Vu et al., 2013). Lipoatrophy occurs 
mainly on the face, arms, buttocks and legs whereas lipohypertrophy occurs at the back of the 
neck or suprapubic region (“buffalo hump”), abdominal adiposity and mammary hypertrophy 
(Guaraldi et al., 2005; Palios et al., 2012; Waters and Nelson, 2007). The incidence of 
lipohypertrophy has varied from 6% (men) to 93% (women) in HAART-treated patients 
(Bonnet, 2010).  
Several mechanisms by which PIs contribute to lipodystrophy have been proposed (Carper et 
al., 2008; Singhania and Kotler, 2011). PIs have been shown to suppress adipocyte 
differentiation by inhibiting cytoplasmic retinoic acid binding protein type 1 (CRABP-1) and 
PPAR-γ (Bonnet, 2010; Tsiodras et al., 2010), which play a role in the differentiation of 
preadipocyte into mature adipocytes (Tsiodras et al., 2010). The catalytic site of HIV-protease 
shares approximately 60% homology region within CRABP-1 region (Carr, 2000; Carr and 
Cooper, 2000). Under normal circumstances, CRABP-1 binds to intracellular retinoic acid 
(RA) and presents it to cytochrome P450 3A, which in turn converts to cis-9-retinoic, a major 
ligand of the retinoic X receptor (RXR) (Dau and Holodniy, 2008; James et al., 2002). Then, 




the heterodimerization of RXR with PPAR-γ significantly enhances the binding affinity of cis-
9-retinoic to RXR (Carr et al., 1998; Dau and Holodniy, 2008; James et al., 2002). The complex 
cis-9-RA-RXR-PPAR-γ, thus enhances the transcription of genes that prevent adipocytes from 
apoptosis and increase adipocytes differentiation (Carr, 2000; Carr et al., 1998; Dau and 
Holodniy, 2008).  Carr et al (1998) suggested that PIs may obstruct CRABP-1, therefore 
preventing CRABP-1 mediated cis-9-RA and decrease stimulation of RXR: PPAR-γ complex. 
This in turn inhibits peripheral adipocyte differentiation, stimulate adipocytes apoptosis and 
sequent hyperlipidaemia (Carr, 2000; Dau and Holodniy, 2008). PIs have also been suggested 
to inhibit cytochrome P450 3A (Aberg, 2009; Carr, 2000), thus reducing conversion of RA to 
cis-9-retinoic, which also contributes to the impairment of peripheral adipocytes differentiation 
and hyperlipidemia (Carr, 2000; Dau and Holodniy, 2008; Singhania and Kotler, 2011). The 
Pls have also been suggested to decrease expression of PPAR-γ (Dau and Holodniy, 2008), an 
adipocyte receptor that regulates peripheral adipocyte differentiation and apoptosis, and 
sequent hyperlipidaemia (Carr et al., 1998; Dau and Holodniy, 2008).  
Moreover, PIs have been suggested to inhibit low density lipoprotein-receptor-related protein 
(LRP) by binding to it homologues sequence of HIV protease catalytic region (Carr and 
Cooper, 2000; Carr et al., 1998; Leow et al., 2003). Low density lipoprotein-receptor-related 
protein is a part of the low density lipoprotein (LDL) receptor group, responsible for taking up 
chylomicron remnants enrich with triglycerides to the liver (Hui, 2003). Therefore, it inhibition 
by PIs reduced clearance of chylomicrons in the liver and breakdown of triglycerides, 
subsequently leading to hyperlipidaemia (Carr et al., 1998; Leow et al., 2003). PIs also 
appeared to inhibit proteasome-mediated breakdown of apolipoprotein B (ApoB) also by 
binding to homologous site of HIV-1 protease (Estrada and Portilla, 2011; Leow et al., 2003; 
Singhania and Kotler, 2011). ApoB is the primary protein part of triglyceride and cholesterol-
rich plasma lipoproteins, serve as enzyme cofactors, ligands of cell-surface receptors as the 




lipids are taken up by tissues (Hui, 2003). Therefore, the inhibition of proteasomal degradation 
resulting in overproduction and circulation of triglyceride-rich lipoproteins (Estrada and 
Portilla, 2011; Leow et al., 2003; Singhania and Kotler, 2011). Recent data from cross-sectional 
studies have validated that compared to healthy individuals, PI-treated patients have an 
increased secretion and reduced clearance of VLDL particles, increased synthesis and reduced 
catabolism of apoB, elevated levels of pro-atherogenic residue lipoproteins and reduced 
activity of lipoproteins lipase (Anuurad et al., 2010; Estrada and Portilla, 2011).    
Pls have also been shown to affect lipoprotein production regulated by sterol regulatory 
element binding proteins (SREBPs) (Carper et al., 2008; Hui, 2003), transcriptional regulators 
of genes involved in lipids and glucose metabolism (Estrada and Portilla, 2011). The SREBPs 
are lipid sensors, triggered by the decreased levels of intracellular lipid (Estrada and Portilla, 
2011; Singhania and Kotler, 2011). They are then transported from the endothelium reticulum 
to the nucleus where they increase expression of genes involved in triglyceride, fatty acids, 
cholesterol synthesis and transportation (Estrada and Portilla, 2011; Singhania and Kotler, 
2011). Thereafter, they are degraded by the proteasomes within the nucleus (Estrada and 
Portilla, 2011; Singhania and Kotler, 2011). The PIs especially indinavir and ritonavir have 
been suggested to activate SREBP-1 and SREBP-2 in the liver (Estrada and Portilla, 2011). 
The accumulation of these regulators in the hepatocytes promotes cholesterol and fatty acid 
synthesis, and decrease triglyceride storage (Estrada and Portilla, 2011; Singhania and Kotler, 
2011). This is followed by the increased circulation of lipids and triggering lipodystrophy and 








 1.3.2 Protease Inhibitors and insulin resistance     
Several mechanisms have been suggested by which PIs induce insulin resistance and diabetes. 
These include suppression of glucose transporters isoform 4 (GLUT4, SLC2A4) function 
(Carper et al., 2008; Singhania and Kotler, 2011) and alteration of secretion of adipokines  such 
as TNF-α, Interlukin- 6 (IL-6), adiponectin, leptin ad resistin (Anuurad et al., 2010; Tsiodras 
et al., 2010). Elevated serum levels of cytokines TNF-α (Waters and Nelson, 2007) and IL-6 
have been observed in adipose tissue of PI-induced insulin resistance (Crawford et al., 2013). 
Mynarcik et al., (2000) demonstrated the high levels of sTNFR-2 (soluble type 2 tumor necrosis 
factor-α) receptors in lipodystrophic patients, reflecting stimulation of TNF-α pathway via 
TNF-α, a well-known insulin resistance inducer (Flint et al., 2009; Tsiodras et al., 2010). It has 
been suggested that TNF-α induces insulin resistance through decreasing insulin receptor 
kinase activity, thus prompting apoptosis and lipolysis by suppressing expression of insulin 
receptor kinase substrate (IRS)-1 and GLUT-4 (Domingo et al., 2005; Loonam and Mullen, 
2012). These alterations have been proposed to occur via diminishing of insulin signalling; 
reduction of anti-lipolytic function of insulin (Rudich et al., 2005); suppression of inhibitory G 
protein-coupled receptors, which result in increased cyclic AMP-levels (Zhang et al., 2002); 
reduced activity of lipoprotein lipase and suppression of lipin, a lipid droplet-associated protein 
that plays a role in protecting adipocyte from hydrolytic action of lipase (Domingo et al., 2005; 
Loonam and Mullen, 2012). 
Interleukin-6 is a cytokine that is also secreted by immune cells, endothelial cells and 
fibroblasts in response to inflammation, destruction of immune cells and tissue damage 
(Bastard et al., 2002; MacDermott, 1996). In adipocytes, IL-6 acts as suppressor of insulin 
signaling in hepatocytes (Bastard et al., 2002; Qatanani and Lazar, 2007). It has been suggested 
to down-regulate insulin receptor substrate (IRS) and up-regulate suppressors of cytokine 
signaling 3 (SOC3; a distinguished negative controller of insulin signaling) (Rieusset et al., 




2004; Wallenius et al., 2002). Due to these actions, it therefore prevents insulin from promoting 
the absorption of fatty acids and glycerol by adipocytes where they are stored as triglycerides 
(Petersen et al., 2005; Stith and Luo, 1994). 
Low levels of adiponectin have been experimentally demonstrated in individuals with acquired 
lipodystrophy and insulin resistance (Leung and Glesby, 2011; Loonam and Mullen, 2012). 
Adiponectin is known as an effective insulin sensitizer (Leung and Glesby, 2011). It has been 
suggested that adiponectin induces insulin sensitivity by activating adenosine monophosphate-
activated protein kinase (AMPK) both in skeletal muscle and the liver, which therefore 
endorses fatty acid oxidation and decreases production of glucose in the liver (Fruebis et al., 
2001; Leung and Glesby, 2011; Qatanani and Lazar, 2007). According to Chaparro et al., 
(2005), PIs could be lowering the concentrations of adiponectin by down-regulating the 
expression of SREB-1/PPAR-γ which mediates it transcription; therefore decreasing insulin 
sensitivity, subsequently leading to insulin resistance.  
Even though PIs are reported not to have an effect on serum leptin expression; the effect on 
leptin in HAART-treated individual depends on the body’s stability between fat loss and 
increased gene expression (Remedi and Nichols, 2009; Tsiodras et al., 2010). Leptin is a 
peptide hormone produced mainly by adipocytes of white adipose tissue (Bastard et al., 2002; 
Remedi and Nichols, 2009). Its secretion is positively related to fat mass, with increasing 
secretion as fat deposal increases (Bastard et al., 2002; Frederich et al., 1995; Friedman, 2009). 
This peptide acts to decrease food intake and to enhance sympathetic nervous system activity 
(Frederich et al., 1995; Friedman, 2009). It is transported across the blood-brain barrier and 
attaches to specific receptor (Ob-Rb) on appetite-regulating neurons and arcuate nucleus of 
hypothalamus, therefore suppressing appetite and increase energy expenditure respectively 
(Ashcroft and Rorsman, 2013; Friedman, 2009). In the arcuate nucleus, leptin induces 
production of POMC and CART to decrease food intake and NPY and AgRP to stimulate food 




consumption (Ashcroft and Rorsman, 2013; Shiozaki et al., 2002). In lipoatrophic patients,  
reduced serum leptin level has been due to the fact that it is mainly found circulating in 
subcutaneous fat (Tsiodras et al., 2010). However, in lipohypertrophic patients, higher leptin 
concentrations have been reported (Tsiodras et al., 2010). The role of resistin (a peptide 
hormone that is known to affect glucose metabolism by antagonizing insulin action) on PI-
inducing lipodystrophy and metabolic abnormalities is not known yet. Despite this, resistin is 
thought to act synergistically with PIs to inhibit adipocyte differentiation and enhance 
lipoatrophy  (Tsiodras et al., 2010). Other adipokines that have been reported in lipodystrophic 
subjects include retinol binding protein- 4, visfatin, acylation stimulating protein, omentin and 
vaspin (Remedi and Nichols, 2009; Tsiodras et al., 2010).  
Glucose transporter isoform 4 is predominantly expressed in skeletal muscle and adipose tissue, 
and is responsible for glucose uptake into the cells (Hruz et al., 2001). In general, insulin binds 
to adipocyte insulin receptor and induces translocation of GLUT 4 from the cytoplasm to the 
plasma membrane, thereby facilitating adipocyte glucose uptake and triglycerides synthesis 
(Hruz et al., 2001; James et al., 1989). The PIs inhibit GLUT 4 action (Carper et al., 2008; 
Koster et al., 2003; Singhania and Kotler, 2011); reduce glucose uptake and triglyceride 
synthesis (Carper et al., 2008; Flint et al., 2009; Singhania and Kotler, 2011). The reduced 
glucose uptake increases glucose concentration in plasma leading to hyperglycaemia (Flint et 
al., 2009; Koster et al., 2003; Leow et al., 2003). The reduction of triglyceride synthesis 
contributes to adipocytes shrinkage and lipoatrophy (Flint et al., 2009; James et al., 2002).  
Flint et al., (2009) reported that the exposure of skeletal muscle, 3T3-L1 adipocytes and 
primary adipocytes to PIs (indinavir, ritonavir and APV), results in suppression of GLUT 4 
transport function but with no effects on GLUT 4 translocation or insulin signalling cascade. 
However, previous studies evaluated the relationship between PI structure and the suppression 
of GLUT-4-related glucose uptake (Heath et al., 2002). Researchers have found that all 




available PIs have analogous phenylalanine-like core structure bounded by hydrophobic 
moieties, and that the peptide suppresses GLUT4 (Heath et al., 2002). All have highly enclosed 
aromatic core peptide bound by hydrophobic moieties similar to the structure enclosed by PIs 
(Heath et al., 2002). Furthermore, PIs have been postulated to induce β-cell dysfunction and 
are linked to impaired glucose stimulated-insulin secretion in pancreatic β-cells (Chandra et 
al., 2009; Koster et al., 2003; Schutt et al., 2004) 
 
 
Figure 1:  Illustration of Protease inhibitors- mediated metabolic syndrome (Flint et al., 2009).  
Copyright permission for reproduction was granted from the author. 
 
However, there is limited information involving PIs exposure to β-cells. Current studies have 
reported that chronic exposure to PIs is associated with pancreatic β-cell dysfunction and 
impairment of insulin secretion (Koster et al., 2003; Schutt et al., 2004). Chandra et al., (2009) 
demonstrated that acute treatment with PIs (nelfinavir, saqunavir, atazanavir) significantly 
inhibited insulin secretion in rat insulinoma cell line (INS-1). Similarly, Koster et al., (2003) 




demonstrated that long-term and acute treatment with PIs (ritonavir, indinavir, saquanavir, 
nelfinavir and atazanavir) significantly inhibited insulin secretion in mouse insulinoma cell line 
(MINS). The mechanisms by which PIs diminish insulin secretion remain elusive (Chandra et 
al., 2009). However, it has been suggested that PI-mediated β-cell dysfunction is associated 
with an increased oxidative stress and decrease ATP synthesis by electron transport chain 
(Chandra et al., 2009).  
1.4 Oxidative stress and Insulin secretion by pancreatic β-cells 
Oxidative stress is defined as an imbalance between the production of ROS and the cellular 
antioxidant enzymes [superoxide dismutase (SOD), glutathione peroxidase (GPx) and 
glutathione (GSH)] (Ahmadi et al., 2013).  It occurs when the production of ROS overpowers 
the detoxification and scavenging ability of antioxidant defenses resulting in cellular damage 
(Ahmadi et al., 2013). Electron flow across the mitochondrial electron transport chain is carried 
out by four inner membrane-associated complexes (I-IV), cytochrome C and carrier coenzyme 
Q (Murphy, 2009). The electron transport chain (ETC) produces ROS [superoxide (•O2), 
hydrogen peroxide (H2O2), and hydroxyl radical (•OH)] normally during cellular respiration 
(Kanno et al., 2003; Murphy, 2009). Superoxide is produced continuously by ETC in small 
amounts, this reaction occurs at ETC complexes I (NADH dehydrogenase) and III 
(ubisemiquinone) (Murphy, 2009; Turrens, 2003).  Superoxide is then scavenged by the 
mitochondrial enzyme manganese superoxide dismutase (MnSOD) to produce hydrogen 
peroxide (Kanno et al., 2003; Kim et al., 2009). Hydrogen peroxide is converted to water 
molecule by GPx or catalase in the present of reduced GSH as a coenzyme, thus entirely 
detoxifying ROS (Murphy, 2009; Turrens, 2003). Excessive generation of H2O2 results in 
production of a highly reactive OH• through Fenton reaction in the presence of ferrous (Fe2+) 
and through Haber-Weiss reaction (Halliwell and Chirico, 1993; Kanno et al., 2003). If there 
is no rapid detoxification of ROS, the ROS turns to oxidize mitochondrial components 




endorsing proteins crosslinking, DNA fragmentation, phospholipids peroxidation and by 
triggering a chains of stress pathways (Sreelatha and Padma, 2011).    
Oxidative phosphorylation in the inner mitochondrial membrane plays a key role in glucose-
induced insulin secretion from the pancreatic β-cells (Chandra et al., 2009; Lowell and 
Shulman, 2005). Glucose equilibrates through the cell membrane and phosphorylated by 
glucokinase which defines the rate of glycolysis and the production of pyruvate (Patterson et 
al., 2014; Wollheim and Maechler, 2002). Pyruvate enters the mitochondrion and act as 
substrate for pyruvate dehydrogenase and pyruvate carboxylase (Patterson et al., 2014; 
Wollheim and Maechler, 2002). This leads to the generation of reducing equivalents 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) from the 
tricarboxylic acid (TCA), which then activates ETC (Wollheim and Maechler, 2002). 
Electrochemical proton gradient is then generated as the electrons are channelled through the 
complexes, and subsequently production of ATP from phosphorylation of ADP via ATP 
synthase as protons is channelled through (Patterson et al., 2014; Wollheim and Maechler, 
2002). ATP-sensitive potassium channel (K+ATP channels) consist of the pore-forming subunit 
K+IR 6.2 and the controlling sulfonylurea receptor 1 (SUR1) (Henquin, 2004). The binding of 
ATP to K+IR 6.2 closes the channel, while binding of Mg ADP to SURI opens the channel 
(Henquin, 2004). Therefore, the increase in ATP/ADP ratio from glucose metabolism, endorses 
the closure of KATP channels and depolarization of the cytosolic membrane  
(Henquin, 2004; Neye et al., 2006). This results in influx of Ca2+ inside the cell through the 
opened voltage-sensitive pump (Henquin, 2004; Neye et al., 2006; Wollheim and Maechler, 
2002). Elevated Ca2+ concentrations trigger the insulin release via exocytosis (Henquin, 2004; 
Wollheim and Maechler, 2002) (Figure 2). 










Figure 2: Overview of glucose metabolism for insulin secretion in the β-cells (Lowell and 
Shulman, 2005). Copyright permission for reproduction was granted from the author. 
Reactive oxygen species induced by PIs have been suggested to impair insulin secretion by 
pancreatic β-cells (Chandra et al., 2009). It has been suggested that superoxide anions activate 
uncoupling protein 2 (UCP2) (Sakai et al., 2003); the inner membrane protein that dissipate the 
proton gradient before it can be used to provide ATP for oxidative phosphorylation (Kim et al., 
2008; Krauss et al., 2003). The up-regulation of UCP2 causes partial depolarization of the 
mitochondrial membrane potential, decrease ATP production, block KATP channels and 
therefore, diminish insulin secretion.  
In addition, hyperglycemia is also identified to increase oxidative stress and cause β-cell 
dysfunction (Sakai et al., 2003). Hyperglycemia has been reported to increase generation of 
ROS by affecting mitochondrial respiration chain in the pancreatic β-cells (Ahmadi et al., 2013; 
Sakai et al., 2003). It has been suggested that hyperglycemia increases generation of electron 
donors from Kreb Cycle NADH and FADH2 (Lowell and Shulman, 2005; Maechler and 
Wollheim, 2001). This increases membrane potential as protons are pumped across the 
mitochondrial inner membrane (Lowell and Shulman, 2005; Maechler and Wollheim, 2001). 




The inner membrane is proportional to electron flux through the respiration chain (Lowell and 
Shulman, 2005; Maechler and Wollheim, 2001). The electron transport at complex lll is then 
suppressed, hence increasing the half-life of free radical intermediates of coenzyme Q which 
then reduces oxygen to superoxide (Lowell and Shulman, 2005; Maechler and Wollheim, 
2001). Increased mitochondrial superoxide activates UCP2-associated proton leakage leading 
to decreased ATP generation and insulin secretion (Brown et al., 2002; Echtay et al., 2002; 
Lowell and Shulman, 2005; Maechler and Wollheim, 2001). Zang et al., (2001) reported that 
UCP2 negatively controls insulin secretion and is a primary link between obesity, β-cell 
dysfunction and type 2 diabetes.  
Dysfunctional or reduced pancreatic β-cell mass are the influential factors in the pathogenesis 
of type 2 diabetes and insulin resistance (Prentki et al., 2002; Unger, 1995). Overproduction of 
mitochondrial ROS endorses susceptibility to cell membranes damage and changing the 
mitochondrial permeability transition (Kim et al., 2008; Park and Han, 2014; Robertson et al., 
2007). This could account for higher percentage of mitochondrial membranes depolarised and 
the release of apoptotic makers such as Bcl-2 family (proteins that controls mitochondrial 
permeabilisation through apoptosis) and cytochrome c (Park and Han, 2014; Robertson et al., 
2007). This results in the formation of apoptosome with cytochrome c, apoptotic activating 
factor (Apaf)-1 and procaspase-9 (Shiozaki et al., 2002). The oligomerisation of procaspase-9 
in apoptosome formed results in the activation of caspase-9 which in turn activates caspase-3 
(Shiozaki et al., 2002). Activated caspase-3 leads to cell death characterized by chromatin 
condensation, nuclear fragmentation, DNA ladder and formation of apoptotic bodies (Shiozaki 
et al., 2002). It has been suggested that PIs should be co-administrared with the drugs used to 
reduce oxidative stress in order to reduce the risk of β-cell dysfunction and impairment of 
insulin secretion (Kalra et al., 2011; Rudich et al., 2001).  




Currently, several clinical trials using antioxidant supplements such vitamin E and C  have 
failed to establish significant improvement in oxidative stress markers in type 2 diabetic 
individuals (Matough et al., 2012; Savini et al., 2013). On the other hand, there is no laboratory 
or clinical data used sulfonylurea agents to evaluate if they can preserve pancreatic β-cell and 
improve insulin secretion in PI-treated patients.  Glibenclamide is a well- known sulfonylurea 
receptor blocker, used to increase insulin secretion in pancreatic β-cells (Luzi and Pozza, 1997; 
Patane et al., 2000). It inhibits sulfonylurea receptor 1, the regulatory subunit of the KATP 
channels in pancreatic β-cells (Luzi and Pozza, 1997; Patane et al., 2000). This inhibition 
causes a cell membrane to depolarize and opens voltage-dependent Ca2+ channel (Luzi and 
Pozza, 1997; Patane et al., 2000). These outcomes in raise in intracellular Ca2+ in the β-cell and 
resultant stimulation of insulin release (Luzi and Pozza, 1997; Patane et al., 2000). Hence, the 
study hypothesized that insulin secretagogues could relieve oxidative stress by boosting insulin 
secretion and cellular anti-oxidant capacity.  
However, plant derived antioxidants are becoming more promising as they can be used as 
nutritional supplements and have less side-effects (Savini et al., 2013).  Naringin (4′, 5, 7- 
trihydroxy flavonone 7-rhamnoglucoside; Figure 3), flavanone glycoside of naringenin found 
in Citrus paradisi has been shown to possess potent antioxidant properties (Gopinath and 
Sudhandiran, 2012; Thangavel et al., 2012). Naringin has been demonstrated to have no known 
side-effects, as individuals have been consuming grapes and other citrus fruits for a long time 
(Thangavel et al., 2012). Naringin occurs naturally in citrus fruit and gives bitter flavour to 
some citrus fruits (Rajadurai and Stanely Mainzen Prince, 2006). It is rapidly hydrolysed to its 
glycoside naringenin by gut bacterial enzymes such as α-rhamnosidase and β-glucosidase 
(Amudha and Pari, 2011; Rajadurai and Stanely Mainzen Prince, 2006) 





Figure 3: The structure of Naringin (4′, 5, 7-trihydroxy flavonone 7-rhamnoglucoside) (Sahu 
et al., 2014). Copyright permission for reproduction was granted from the author.    
Flavonoids have three chemical structures that confer on them their remarkable antioxidant 
properties; the hydroxyl groups attached to the aromatic ring structures of flavonoids, which 
allows them to undergo a redox reaction that helps to scavenge free radicals more easily; 
Certain structural groups which are capable of forming transition metal-chelating complexes 
that can regulate the production of ROS such as hydroxyl and oxygen radicals; Aromatic, 
heterocyclic rings and multiple unsaturated bonds, which enables delocalization system 
(Cavia-Saiz et al., 2010; Thangavel et al., 2012). Furthermore, naringin possesses metal-
chelating complexes, antioxidant and free radical scavenging properties that have been reported 
to protect against lipid peroxidation (Gopinath and Sudhandiran, 2012).  
Naringin has been demonstrated to ameliorate oxidative stress both in vitro and vivo studies. 
Amudha and Pari (2011) evaluated the valuable role of naringin on nickel induced 
nephrotoxicity and the findings showed that naringin treatment reversed the alterations in renal 
and urine markers, reducing lipid peroxidation and enhanced antioxidative cascade. All the 
alterations were supported by histopathological observations. Akondi et al (2011) showed a 
significant reduction of free radical generation in the testes of male rats that had undergone 
torsion when exposed to naringin. In addition, Thangavel et al., (2012) demonstrated that 




naringin prevents liver damage, lipid peroxidation and preserves the antioxidant defence 
system in diethyl nitrosamine (DEN)-induced liver carcinogenesis in male Wistar rats. 
Furthermore, naringin has also been reported to possess pharmacological properties such as 
anti-inflammatory, anticancer, antimicrobial cholesterol lowering activities (Gopinath and 
Sudhandiran, 2012; Rajadurai and Stanely Mainzen Prince, 2006; Thangavel et al., 2012). 
Recent studies have reported that naringin also possessed antiapoptotic activities against ROS-
induced injuries (Cavia-Saiz et al., 2010; Chen et al., 2014). Naringin has been shown to block 
mitogen-activated proteins kinases (MAPKs) pathway induced by oxidative stress in different 
cell lines (Kim et al., 2009). In human neuroblastoma,  SH-SY5Y cells (Kim et al., 2009) and 
H9c2 cardic cells (Chen et al., 2014), naringin has been shown to inhibit JNK pathway against 
rotenone-induced apoptosis and hyperglycaemia-induced cytotoxicity respectively.   
MAPKs are known as serine-threonine protein kinases essential for signal transduction from 
extracellular surface to the nucleus (Goillot et al., 1997; Wada and Penninger, 2004).  They 
consist of extracellular signal-related kinases (ERKs), p38 MAPKs, c-Jun NH2 terminal kinase 
(JNK) and stress-activated MAPKs (Goillot et al., 1997; Wada and Penninger, 2004). They are 
components of a three-kinase signalling regulate composed of the MAPK, MAPK kinase 
(MAP2K) and MAPK kinase (MAPK3K) (Goillot et al., 1997; Wada and Penninger, 2004). 
These MAPK pathways regulate diverse cellular functions such as cell differentiation, 
proliferation, migration and apoptosis (Wada and Penninger, 2004). Studies have demonstrated 
that oxidative stress trigger MAPK pathway but the mechanism is not fully understood (Chen 
et al., 2014). However, it has been suggested that overproduction of ROS tends to oxidize 
intracellular kinases (e.g. MAP3Ks) that are involved in MAPK signalling cascade (Chen et 
al., 2014). Apoptosis signal-regulating kinase 1 (ASK-1) is an associate of the MAP3K super-
intimate for JNK and p38. It oxidises the reduced thioredoxin and oxidize thioredoxin 
disassociate from ASK-1 leading to the stimulation of JNK and p38 pathway via 




oligomerization of ASK-1 (Chen et al., 2014). Stimulated JNK causes the release of 
apoptogenic factors such as cytochrome c and second mitochondrial-derived activator of 
caspases (smac)/DIABLO from the mitochondrial therefore initiating apoptosis, whereas p38 
is involved in the phosphorylation of Bcl2 family and stimulation of the mitochondrial 
apoptotic pathway (Chen et al., 2014). Based on these findings, it is therefore postulated that 
naringin could ameliorate the impairment of insulin secretion and preserve pancreatic β-cell 
integrity by reducing oxidative stress.  
 
1.6 Aim and Objectives 
To investigate whether naringin could reverse HIV-1 protease inhibitors-associated pancreatic 
β-cell dysfunction with respect to: glucose-induced insulin secretion, β-cell viability, oxidative 







                                                        
                                                         
 
                                                             
 




                                                         CHAPTER TWO 
2.  Materials and Methods 
2.1 Chemicals and reagents  
The rat insulinoma cell lines (RIN-5F) were purchased from European Collection of Cell 
Cultures (ECACC). All cell culture reagents, the PIs (nelfinavir, saquinavir, atazanavir, 
glibenclamide) naringin, glucose and the Super Oxide Dismutase (SOD) assay kit were 
purchased from Sigma Chemical (St Louis, MO). ATP assay kit was purchased from Biovison 
(Mountain View, CA). The GSH-GloTM Glutathione assay was obtained from Whitehead 
Scientific (Johannesburg, South Africa). Caspase-Glo®-9 assay kit was purchased from 
Promega (Madison, USA) and caspase-3 fluorescence kit was bought from Cayman Chemical 
Company (Canada, USA). Rat insulin ELISA kit was purchased from Alpha Diagnostics 
(Salem, NH).  
2.2 Cell culture 
The RIN-5F cells were cultured within 40 passages in 75 cm3 flasks in RPMI-1640 medium 
containing 11.1 mM glucose supplemented with 10% Fetal Bovine Serum (FBS), 10% 
penicillin-streptomycin, 10.0 mM HEPES and 1.0 mM sodium pyruvate. The cultures were 
maintained at 37°C in humidified with 5% CO2.  
2.3 Trypsinisation and cell counting 
Trypsinisation process was done to detach cells from the culturing vessel once they reached 
80% confluency, and also to sub-culture and seed the cells for the various biochemical assays.  
This process involved rinsing the cells three times with warm 0.1M PBS (3 ml; 37°C) and 
incubating the cells with trypsin-EDTA (1 ml) for 2 min. The cells were then observed for 
roundness using an inverted light microscope (Olympus IXSI; 20 x).  Once they were found to 




be round, trypsin was discarded and CCM (5 ml) added to the flask. The flask was agitated to 
removed cells from culturing vessel and the cell suspension was counted using 
haemocytometer. Trypan blue (0.4%) was applied in a dye exclusion procedure for cell 
counting. The principle of dye exclusion is based on damaged/dead cell membranes which 
allow entry of the dye into the cells and the cells stain blue whereas sustainable cells remain 
unstained. 
2.4 Protease Inhibitors (PIs) preparation  
Nelfinavir (Viracept) and saquinavir (Inviraset) were initially dissolved in ethanol (100%, w/v) 
to a stock concentration of 10.0 mg/ml (15 mM) and 2.0 mg/ml (2.6 mM) respectively. 
Atazanavir (Reyatazt) was dissolved in de-ionized water to a stock concentration of 4 mg/ml 
(7.3 mM). Glibenclamide was dissolved in dimethylsulfoxide (DMSO) to a final concentration 
of 20.0 mM, and naringin was dissolved in DMSO to a stock concentration of 20 mg/ml (5 
mM).  
2.5 Cell exposure 
To measure the effects of PIs on insulin levels, the cells were plated in 6-wells plates (5.0× 105 
cells/well) in the presence of 11 mM glucose only and allowed to grow to 80% confluence, 
followed by treatment with nelfinavir (0.0, 1.0, 2.5, 5.0, 7.5 and 10 µM), saqanavir (0.0, 1.0, 
2.5, 5.0, 7.5 and 10 µM), atazanavir (0.0, 5.0, 10.0, 15.0, 20.0 and 25.0 µM) for 24 hr. To 
measure glucose-induced insulin secretion, cells were similarly exposed to nelfinavir (10.0 
µM), saquinavir (10.0 µM), atazanavir (20.0 µM), nelfinavir (10.0 µM) plus glibenclamide 
(10.0 µM), saquinavir (10.0 µM) plus glibenclamide (10.0 µM) and atazanavir (20 µM) plus 
glibenclamide (10 µM) at 11, 15, 20 and 25 mM glucose, respectively for 24 hr. Vehicle 
controls constituted Cell Culture Medium (CCM) with or without glibenclamide (10.0 µM) 
were applicable. 




To measure the dose-dependent of naringin on insulin secretion, cells were similarly plated in 
6-wells plates (5.0× 105 cells/well) in the presence of 11 mM glucose only, allowed to grow to 
80% confluence, followed by treatment with naringin (0.0, 10.0, 20.0, 30.0, 40.0 and 50 µM) 
for 24 hr. 
To investigate the role of PIs relative to naringin on RIN-5F cells, cells were exposed to 
nelfinavir (10.0 µM), saquinavir (10.0 µM), atazanavir (20.0 µM), nelfinavir (10.0 µM) plus 
naringin (10.0 µM), saquinavir (10.0 µM) plus naringin (10.0 µM) and atazanavir (20 µM) plus 
naringin (10 µM) in the presence of 11 mM glucose only for 24 hr. Vehicle controls constituted 
CCM with or without naringin (10.0 µM) were applicable. 
For lipid peroxidation, ATP and caspase-3 and -9 assays, cells were cultured to 90% confluency 
in 25cm2 tissue flasks and treated with test compounds. For the GSH assay, the cells (1.0×104 
cells/well) were plated in 96-well microtiter plates and allowed to attach overnight, and 
similarly treated with test compounds. After the treatments, cells were harvested and subjected 













2.6 Biochemical Analysis 
2.6.1 Insulin ELISA 
Rat Ultrasensitive ELISA was used to measure insulin secretion as per manufacturer’s 
instructions. In brief, the cells were incubated with Krebs Ringer Bicarbonate Buffer (KRBB-
140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 10 mM 
HEPES, 2 mM NaHCO3, pH 7.4) with 0.1% BSA in duplicates for 5 min, followed by 
stimulation with 0-25 Mm glucose in  KRBB with for 0.1% BSA for 30 min at 37ºC.  The 
supernatant was collected, centrifuged at 12000 x g for 10 mins at 4ºC and the cells lysed to 
determine the protein content by Bradford method as previously described (Bradford, 1976). 
Twenty five µl of standards, supernatant from controls and samples were added to the primary 
antibody coated wells of the ELISA. Enzyme conjugated 1   x solution (100 µl) was added into 
each well and incubated the plate on a shaker at 800 rpm for 2.0 hr at room temperature (18-
25 °C). After 6 times washes with buffer, 200 µl of substrate TMB was added into each well 
and incubated in a dark for 15 min at room temperature. The reaction was then stopped by 
adding 50 µl of stop solution to each well, mixed well on a shaker (700 rpm) for 5 sec. And the 
absorbance was read at 450 nm using EZ read 400 microplate reader (Biochrom Ltd, 
Cambridge, UK). The values obtained from standard curve were expressed as ng of insulin 
secretion per mg of total cellular protein.  
2.6.2 ATP assay 
The ATP quantification assay used in this study used bioluminescence as per the 
manufacturer’s instructions. This assay is constructed on the conversion of a luciferase- 
inactive derivative to D-luciferin in the presence of Mg2+. Luciferase substrate reacts with 
luciferase to produce oxyluciferin and yield ATP in form of luminescence (Figure 4). This 
luminous signal is directly proportional to the concentration of ATP existing in the cells.  





Figure 4: Principle of the ATP assay for the quantification of cellular ATP (Schafer et al., 
2009). Copyright permission for reproduction was granted from the author. 
ATP levels were measured using EnzyLight TM ADP/ATP Ratio Assay kit. Cells (104/well) 
were cultured in white opaque microplate in triplicates, trypsinized and respendend in 10 µl of 
culture medium.  ATP reagent (90 µl) which was prepared acccording to manufactures 
guidelines was then added into each well and mixed by tapping the plate. After incubation for 
1 min at room temperaturel light signal relative to the cellular ATP content was detected on 
ModulusTM microplate luminometer (Turner Biosystems, Sunnyvale, USA). The values 
obtained were expressed as mean relative light units (RLU). 
2.6.3 Oxidative stress assay 
Malondialdehyde (MDA) is the end product of lipid peroxidation and an indicator of oxidative 
stress. This technique is based on the reaction of two molecules of Thiobarbturic Acid (TBA) 
with one molecule of MDA to form pink colour (Figure 5), then the MDA concentration can 
be measured by microliter plate reader.  





Figure 5: The reaction of malondialdehyde with thiobarbituric acid (Cayman Chemical 
Protocol).https://www.google.co.za/search?q=The+reaction+of+malondialdehyde+with+thio
barbituric+acid&biw=939&bih=403&source=lnms&tbm3B385 
To investigate the PIs-mediated generation of reactive oxygen species (ROS), Thiobarbituric 
acid reactive substances (TBARS) assay was used to assess the levels of MDA according to 
the modified method of Halliwell and Chirico (1993). After 24 hr treatment, 100 µl of 
supernatant from each treated well and controls were aliqouted into glass tubes in triplicates.  
In another set of test tubes, 200 µl of serially diluted MDA standard was added to 500 µl of   
2% H3PO4, 400 µl of 7% H3PO4 and 400 µl of BHT/TBA solutions, respectively. Reactions in 
both sets of tubes were initiated with 200 µl of 1M HCl. All the tubes were incubated in a 
shaking boiling water bath (100 °C) for 15 min and allowed cooled at room temperature. n-
Butanol (1.5 ml) was then added to each tube and thoroughly mixed then centrifuged (13000 
rpm, 24 °C, and 6 min) before 100 µl of the top phase was transferred to a 96-well micro-plate 
in triplicates and read at 532 nm and 600 nm using Spectrostar ® micro-plate reader (Biochrom 
Ltd, Cambridge, UK). The plasma MDA concentrations were calculated using an extinction 
coefficient of 1.56 × 105 M-1 cm-1.   
 
 




2.6.4 Superoxide dismutase assay 
SOD enzymes catalyses the dismutation of superoxide anion into hydrogen peroxide and 
oxygen molecule, thus reduces the cytotoxic. SOD assay measures SOD activity in vitro. This 
technique uses WST-1 that produces a water-soluble formazan product as superoxide anions 
are being reduced. The rate of reduction with a superoxide anion is directly proportional to the 
xanthine oxidase activity, and is reserved by SOD activity (Figure 6).  
 
Figure 6: The principle of determination of SOD activity by SOD assay (Sigma Chemical 
Protocol).https://www.google.co.za/?gfe_rd=cr&ei=2Tv0VKXYL5Cp8wfkk4GoBw&gws_r
d=ssl#q=The+principle+of+determination+of+SOD+activity+by+SOD+assay+      
Superoxide dismutase activity was assessed using SOD assay.  Following treatment, RIN-5F 
cells (1.0×104) were washed with cold 0.1 M Phosphate Buffer Saline (PBS) then added 0.5 ml 
of cold lysis buffer (2.5M NaCl, 100 mM EDTA, 1% Triton X-100, 10 mM Tris (pH 10) and 
10% DMSO). After 10 min on ice, the lysate was centrifuged at 12, 000 × g for 5 min at 4º C). 
Supernatant (20 µl) was then added in triplicates to the wells in a 96-well microtitre plate. 
Water-Solution tretrazolium and enzyme working solutions were prepared according to 
manufacturer’s guidelines. Water-Solution tretrazolium solution (200 µl) was then added each 
well followed by 20 µl of enzyme working solution incubated at 37°C for 20 min. Absorbance 
was measured at 450 nm using EZ 400 reader microplate (Biochrom Ltd, Cambridge, UK). 




Sample concentrations were extrapolated from standard curve and values were expressed in 
units of enzyme normalized to cellular protein in milligram (mg).      
2.6.5 GSH-GloTM Glutathione Assay 
Glutathione (GSH) is a tripeptide (cysteine, glycine and glutamine) that plays a role in the 
detoxification of electrophilic and peroxide species. This assay is based on the conversion of 
luciferin derivative (Luc-NT) into luciferin in the presence of glutathione, catalysed by GST. 
The light signal that is produced is coupled to luciferase reaction, proportional to the quantity 
of glutathione that is present (Figure 7). 
                                                                                          
Figure 7: The principle of the GSH-Glo™ Glutatione assay (Promega Protocol). 
http://www.promega.com/~/media/Files/Resources/Protocols/Technical%20Bulletins/101/GS
H-Glo%20Glutathione%20Assay%20Protocol.pdf 
                                                                                                                                                                                                                                                                  
Glutathione-Glo™ Assay (Promega) was used according to manufacturer’s recommendations 
to quantify intracellular glutathione levels. Harvested cells suspensions were diluted in 0.1 M 
PBS and 50 µl (105 cells/well) dispensed into 96 well plate in triplicates followed by 50 µl of 
GSH-GloTM. The reagents were mixed well by shaking on a mechanical shaker then incubated 
at room temperature for 30 min. To each well was then added 100 µl of reconstituted Luciferin 
Detection Reagent, mixed briefly on a plate shaker then incubated for 15 min at room 
temperature. Glutathione standards (0-5 µM) were prepared from a 5 mM stock diluted in 




deionized water. Luminescence was detected on a ModulusTM microplate luminometer (Turner 
Biosystems, Sunnyvale, USA). GSH concentrations in each sample were extrapolated from the 
standard curve and expressed as mean Relative Light units (RLU). 
2.6.6 Analysis of apoptotic markers 
2.6.6.1 Caspase-Glo®-9 assay kit  
Caspase-Glo® 9 assay is a luminescent assay that measures activity of caspase-9. This assay is 
based on the cleavage of substrate Ac-LEHD-p-NA by active caspase-9. Then, the luminescent 
signal generated through mono-oxygenation of amino-luciferin can be quantified on a 
ModulusTM microplate luminometer (Figure 8). The luminescent signal generated is directly 









RIN-5F cells (1.0×104) were seeded into an opaque polystyrene 96-well microtitre plate in 
triplicates. Following treatment, Caspase-Glo® 9 reagent was prepared according to 
manufacturer’s instructions then added 100 µl of Caspase-Glo® 9 reagent to each well. The 
plate placed on a shaker (300-500 rpm) for 30 seconds and incubated in the dark for 30 min at 




room temperature. Luminescence was measured on a Modulus™ microplate luminometer. The 
data was expressed as relative light units (RLU).   
2.6.6.3 Caspase-3 fluorescence assay kit 
Caspase-3 fluorescence assay measures the activity of caspase-3. This assay is based on the 
cleavage of specific caspase-3 substrate, N-Ac-DEVD-MC-R110 by active caspase-3, which 
then generates a fluorescent product that can be quantified using excitation and emission 
wavelength of 485 and 535 nm (Figure 10). The fluorescent signal produced is directly 





                     
 
Figure 9: Principle for the detection of caspase-3 activity (Cayman Chemical Protocol). 
https://worldwide.promega.com/~/media/files/resources/protocols/technical%20bulletins/101/
caspase-glo%203%207%20assay%20protocol.pdf 
RIN-5F cells (5×104) were seeded in a 96-well plate for the assay of caspase-3 activities using 
caspase-3 fluorescence assay according to manufacturer’s recommendations. Caspase-3 assay 
buffer (200 μl) was then added to each well in triplicates and centrifuge (800 × g, 5 min) at 
room temperature. The supernatant from each well was aspirated and cell-based assay buffer 
(100 µl) added and the plate incubated with gentle shacking on an orbital shaker for 30 min at 




room temperature.  The plate was then centrifuged at 800 × g for 10 min at room temperature 
and 90 µl of the supernatant was transferred from each well to a corresponding 96-well plate. 
Caspase -3 inhibitor solution (10 µl) was then added to appropriate wells, followed by addition 
of active capsase-3 standards (100 µl) into the corresponding wells. Thereafter, 100 µl of 
caspase-3 substrate solution was added to each well and the plate incubated at 37°C for 30 min. 
The fluorescence intensity was then measured on a Modulus™ microplate luminometer at the 
excitation of 485 nm and emission of 535 nm. 
 
 
3.0 Statistical analysis 
The data are presented as mean ± SD and analysed by Graph pad Prism Software Version 5.0. 
Mann-Whitney tests and/or Student t-tests were applied to the results to determine statistical 
significance. P ≤ 0.05 was considered as statistically significant. 







                                                      




                                                      CHAPTER THREE  
Results   
3.1 Insulin ELISA  
Increasing concentrations of glucose (11-25 mM) caused increased levels of insulin secretion 
in cells with or without PIs and/or glibenclamide (Figure 10 A and B). However, insulin 
secretions at all glucose concentrations were significantly (p < 0.05) lower in the presence of 
different PIs (nelfinavir, saquinavir and atazanavir) compared to the control group. However, 
there was no significant difference in insulin secretion among the different PIs individually 
(Figure 10 A). 
Similarly, insulin secretion by RIN-5F cells at all glucose concentrations were significantly (p 
< 0.05) lower in the presence of both PIs and glibenclamide compared to treatment with 
glibenclamide alone. There was no significant difference in insulin secretion among 
combination of single PIs with glibenclamide (Figure 10 B). 
Furthermore, insulin secretion by cells at different glucose concentrations was higher in the 
presence of glibenclamide and also in combination with different PIs plus glibenclamide 
(Figure 10 A and B) compared to PI-treated cells only.        
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Figure 10: Glucose-induced insulin secretion in cells that were treated with (A) PIs and/or (B) 















3.2 ATP assay 
Increasing concentrations of glucose from 11 to 25 mM caused increases in the levels of ATP 
in cells with or without PIs or glibenclamide (Figure 11 A and B). However, ATP levels at all 
glucose concentrations were significantly (p < 0.05) reduced in the presence of PIs (nelfinavir, 
saquinavir and atazanavir) compared to the control groups (without PIs) (Figure 11 A).  
Similarly, ATP levels at all glucose concentrations were significantly reduced in the presence 
of PIs plus glibenclamide compared to treatment with glibenclamide alone (Figure 11 B). 
Saquinavir was associated with significantly (p < 0.05) less ATP production with or without 
glibenclamide compared to nelfinavir or atazanavir (Figure A and B).   
Finally, ATP levels in cells at different glucose concentrations were higher in the presence of 
glibenclamide than without glibenclamide and with different PIs plus glibenclamide (Figure 
12 A and B).            
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Figure 11: ATP productions after cells were treated with (A) PIs and/or (B) glibenclamide at 
different concentrations of glucose. (*p < 0.05 when compared to controls, ᶺp < 0.05 compared 
to nelfinavir and atazanavir, respectively).   




3.3 Insulin ELISA 
The insulin secretion was measured in RIN-5F cells exposed to different concentrations of PIs; 
(nelfinavir (1-10 µM), saquinavir (0-10 µM) and atazanavir (5-20 µM) for 24 h. Linear 
regression analysis showed significant decrease in insulin levels in response to nelfinavir, 
saqunavir and atazanavir (r2= 0.86, 0.76, 0.95, respectively)  in a dose-dependent manner 
(Figure 12). However, atazanavir appears to have a more enhanced suppressive effect on 
insulin secretion compared to nelfinavir and saquinavir.   





















Figure 12: Linear regression analysis of concentration-depend inhibition of insulin secretion in 
RIN-5F cultured cells.  Nelfinavir: r2 = 0.86; saquinavir: r2 0.76 and atazanavir: r2 = 0.95                                                                       
3.4 Lipid peroxidation 
There was a significant increase in MDA levels as glucose concentration increased from 11 
mM to 25 mM with or without PI or with PI plus glibeclamide but not in the presence of 
glibenclamide alone. The MDA levels at all glucose concentrations were significantly (p < 
0.05) higher in the presence of different PIs compared to the controls (Figure 13 A). The MDA 
levels in the presence of the different PIs was not statistically significantly different at all 
glucose concentrations, except at 25 mM where atazanavir caused a significantly (p < 0.05) 
lower MDA concentrations compared to nelfinavir and saquinavir (Figure 13 A).  




Furthermore, MDA levels at all glucose concentrations were significantly higher in the 
presence of the PIs plus glibenclamide compared to treatment with glibenclamide alone (Figure 
13 B). At 25 mM glucose concentration, atazanavir plus glibencamide caused a significantly 
lower MDA concentrations compared to nelfinavir plus glibenclamide and saquinavir plus 
glibenclamide while MDA concentration of the different PIs plus glibenclamide did not differ 
statistically at other glucose concentrations (Figure 13 B). Glibenclamide blunted lipid 
peroxidation at all glucose concentration.  
Finally, MDA levels at different glucose concentrations were lower in the presence of 
glibenclamide than without glibenclamide or with different PIs (Figure 13 A and B)                               
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Figure 13: TBARS assay measured as MDA concentrations after cells were treated with (A) 
PIs and/or (B) glibenclamide at different concentrations of glucose. (*p < 0.05 when compared 
to controls, respectively, ᶺp<0.05 compared to nelfinavir and saquinavir). 
 
 




3.5 Superoxide dismutase (SOD) assay   
Total SOD activities significantly (p < 0.05) increased with increased glucose concentrations 
(11-25 mM) and also with exposure to nelfinavir, saquinavir and atazanavir compared to 
controls, respectively (Figure 14 A). However, after treatment with glibenclamide SOD 
activities significantly (p < 0.05) increased in controls but decreased in cells that were treated 
with nelfinavir, saquinavir or atazanavir (Figure 14 B).     
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Figure 14: SOD activity after cells were exposed with (A) PIs and/or (B) glibenclamide at 
different concentrations of glucose. (*, ᶺ, ∂ p<0.05 when compared to controls, nelfinavir and 
saquinavir or saquinavir, respectively).    
3.6 Glutathione (GSH) assay 
GSH concentrations were significantly reduced (p < 0.05) in cells that were exposed to PIs 
compared to controls as glucose concentration increased (Figure 15 A).  However, at 11 mM 
glucose, controls had higher levels of GSH which dropped as glucose concentration increased. 
In PI-treated cells, GSH levels were low then increased to maximum at 15 mM glucose 
concentration then decreased glucose concentration increases. There was no difference 
observed in GSH levels between the control and PIs at 25 mM glucose (Figure 15 A).   




Glibenclamide significantly (p < 0.05) increased GSH levels in a glucose dose-dependent 
manner (Figure 15 B). Co-treatments (nelf+glibn, saq+glibn and ata+glibn) had an increased 
GSH levels respectively in a dose-dependent manner compared to PIs only.                                                                     
                                         
                                         A                                                                                 B 
                                                                                              
Figure 15: Glutathione levels after cells were exposed with (A) PIs and/or (B) glibenclamide 
at different concentrations of glucose. (*p < 0.05 when compared to controls, respectively).                                                             
3.7 Caspase assays  
3.7.1 Caspase-3 Fluorescent assay 
Caspase-3 activities increased with glucose concentrations in the medium. There was no 
significant (p < 0.05) difference in caspase-3 activities in control and glibenclamide-treated 
cells at baseline glucose concentrations (11 mM). However, at higher glucose concentrations 
(20-25 mM), glibenclamide significantly (p < 0.05) reduced caspase-3 compared to controls. 
Nelfinavir, saquinavir and atazanavir all exhibited increases in caspase-3 activities while in the 
presence of glibenclamide, the activities were significantly (p < 0.05) decreased in a glucose-
dependent manner, respectively (Table 2).    
Table 2: Caspase-3 activities expressed as Relative Fluorescence Units (RFU) in RIN-5F cells 
treated with PIs and glibenclamide at different concentrations of glucose. 




                                                              Mean ± SD 
 
Glucose Mm 
11 15 20 25 
Control  317.1 ± 4.2 330 ± 0.6 632.7 ± 31.6 748.2 ± 4.1 
 Glibenclamide 313.4 ± 11.5 368.5 ± 29.0 327.6 ± 8.5* 340.8 ± 11.0* 
Nelfinavir  613.2 ± 16.9#1 1354 ± 71.8#1 3115 ± 23.0#1 4113 ± 129.1#1 
 Glibenclamide 451.1 ± 5.6# 857.7 ± 5.5# 932.6 ± 31.7# 1233 ± 31.3# 
Saquinavir  688.1 ± 11.3ᶺ1 1469 ± 32.4ᶺ1 3399 ± 31.4ᶺ1 4343 ± 59.0ᶺ1 
 Glibenclamide 429.5 ± 4.8ᶺ 929.9 ± 16.5ᶺ 1131 ± 127.2ᶺ 1317 ± 23.8ᶺ 
Atazanavir  671.1 ± 8.4ɵ1 1400 ± 1.5 ɵ1 3042 ± 57.0 ɵ1 4249 ± 49.74ɵ1 
 Glibenclamide 498.6 ± 13.4ɵ 749.5 ± 38.9ɵ 939.1 ± 63.7ɵ 1210 ± 4.2ɵ 
*, #1, ᶺ1, ɵ1 p < 0.05 compared to the controls; #, ᶺ, ɵ p < 0.05 compared to nelfinavir, saquinavir and atazanavir, 
respectively 
    
3.7.2 Caspase-Glo® 9 assay 
Caspase-9 activities increased with glucose concentrations increased from in the medium. 
There was no significant (p < 0.05) difference in caspase-9 activities in control and 
glibenclamide-treated cells at baseline glucose concentrations (11 mM). Nevertheless, at higher 
glucose concentrations (20-25 mM), glibenclamide significantly (p < 0.05) reduced caspase-9 
activities compared to controls. All PIs (nelfinavir, saquinavir and atazanavir) exhibited 
increases in caspase-9 activities while in the presence of glibenclamide, the activities were 
significantly (p < 0.05) decreased in a glucose-dependent manner, respectively    (Table 3).  
Table 3: Caspase-9 activities Relative Light Units (RLU) x 102 in RIN-5F cells treated with 
PIs and glibenclamide at different concentrations of glucose.  




 *, #1, ᶺ1, ɵ1 p < 0.05 compared to the controls; #, ᶺ ,ɵ p < 0.05 compared to nelfinavir, saquinavir and atazanavir, 
respectively 
 
     
      







Mean RLU ± SD 
Glucose Mm 11 15 20 
 
25 
Control  125.70 ± 35.91 145.80 ± 6.449 310.10 ± 1.322 472.90 ± 91.58 
 Glibenclamide 100.80 ± 1385 122.40 ± 0.7* 270.10 ± 28.38* 353.90 ± 2.291 
Nelfinavir  281.90 ± 45.64#1 380.20 ± 15.91#1 758.40 ± 65.27#1 1485 ± 41.73#1 
 Glibenclamide 175.30 ± 21.46# 286.50 ± 7.283# 489.20 ± 91.97# 705.60 ± 19.76# 
Saquinavir  320.70 ± 15.11ᶺ1 458.80 ± 20.73ᶺ1 834.3 ± 53.92ᶺ1 1566 ± 13.76ᶺ1 
 Glibenclamide 216 ± 6.06ᶺ 299.20 ± 15.27ᶺ 445.50 ± 73.91ᶺ 742.10 ± 17.67ᶺ 
Atazanavir  283.10 ± 15.63ɵ1 425.60 ± 7.775 ɵ1 715.60 ± 11.02ɵ1 1353 ± 19.70ɵ1 
 Glibenclamide 165.20 ± 47.96ɵ 281.60 ± 24.77ɵ 475.80 ± 44.94ɵ 666.70 ± 16.16ɵ 




3.8.0 Naringin  
3.8.1 The effect of naringin on insulin secretion  
Insulin secretion increased with naringin concentrations. Linear regression analysis showed 
significant correlation (r2 = 0.9589, 95% Cl= 0.01490 to 0.02692) (Figure 16).   




















Figure 16: A dose-dependent increase insulin secretion in cells after naringin (0-50 µM) 
treatment for 24 h at 11 mM glucose concentration.     
 
3.8.1 The effect of naringin on lipid peroxidation.   
 
The MDA concentrations on PI exposure were higher (p < 0.0001) compared to untreated 
controls (Figure 17) at 11 mM glucose concentrations. However, the combination of naringin 
plus PI treatment significantly (narg+nelf; p < 0.0001, narg+saq; p < 0.0001 and narg+ata; p < 
0.0001) reduced MDA concentrations compared to the respectively cells treated with PIs alone, 
respectively There was no significant difference in MDA concentrations between naringin and 
controls.     
 






























































    
Figure 17: Malondialdehyde levels in RIN-5F cells treated with PIs and/ or naringin (10 µM) 
for 24 h at 11 mM glucose concentration. (***p < 0.0001 compared to controls, αp < 0.0001 
compared to nelfinavir, δp < 0.0001 compared to saquinavir and εp < 0.0001 compared to 
atazanavir respectively) 
 
3.8.2 The effect of naringin on antioxidants  (superoxide dismutase) 
 
The SOD activity in PIs exposure was significantly (p < 0.0001) increased compared to controls 
(Figure 18). However, the combined treatment of naringin plus different PIs significantly 
(narg+nelf; p < 0.0001, narg+saq; p < 0.0001 and narg+ata; p < 0.0001) reduced SOD activities 
compared to the cells treated with PIs alone. There was no significant difference in SOD 
activities between naringin and control.        









































































Figure 18: Superoxide dismutase activity after cells were exposed to PIs and/ or naringin (10 
µM) for 24 hours at 11 mM glucose concentration. (***p < 0.0001 compared to controls, @p < 
0.0001 compared to nelfinavir, #p < 0.0001 compared to saquinavir and $p < 0.0001 compared 
to atazanavir respectively) 
 
3.8.3 The effect of naringin on antioxidant (Glutathione) 
 
The GSH levels in PI exposure were significantly (p < 0.0001) decreased compared to the 
untreated controls (Figure 19). However, cells exposed to combined treatment had significantly 
(narg+nelf; p < 0.0001, narg+saq; p < 0.0001 and narg+ata; p < 0.0001) higher GSH levels 
compared to cells treated with PIs alone. There was no significant difference in intracellular 
GSH levels between cells treated with naringin only and controls.  
 

















































Figure 19: Glutathione levels after cells were exposed to PIs and/naringin (10 µM) for 24 hours 
at 11 mM glucose concentration. ***p < 0.0001 compared to controls,   p < 0.0001 compared to 
nelfinavir, ●p < 0.0001 compared to saquinavir and  ♦p < 0.0001 compared to atazanavir 
respectively 
 
3.8.4 The effects of naringin on ATP levels 
 
The ATP levels in PI exposure were significantly (p < 0.0001) decreased compared to untreated 
controls, but were significantly higher in co-exposure (narg+nelf, narg+saq and narg+ata) 
compared to cells exposed to PIs alone (Figure 20). There were no significant differences in 






























































Figure 20: ATP levels after cells were exposed to PIs and/ or naringin (10 µM) for 24h at 11 
mM glucose concentration. . ***p < 0.0001 compared to controls, ep < 0.0001 compared to 




3.8.5 The effect of naringin on pro-apoptotic markers  
The caspase-3 and -9 activities in PIs exposure were significantly increased (p < 0.0001; p < 
0.0001) compared to the controls, respectively. However, the combined treatment of naringin 
and PIs significantly (narg+nelf; p < 0.0001, narg+saq; p < 0.0001 and narg+ata; p < 0.0001) 
had reduced both caspase-3 and -9 activities compared to the cells treated with PIs alone, 
respectively. There were no significant differences in caspase-3 and -9 respectively between 










Table 4: Mean values of Caspase-3 and -9 activities in RIN-5F cells treated with PIs and naringin 
for 24 h at 11 mM glucose concentration.   
 Mean  ±SD Mean  ±SD 
Treatments Caspase-3 Caspase-9 
Control  317.1 ± 4.240 12570 ± 3591 
 Naringin 316.4 ± 8.6 12220 ± 917.1 
Nelfinavir  668.2 ± 24.0*** 28190 ± 4564*** 
 Naringin 322.9 ± 10.8∞ 13710 ± 1152ᴥ 
Saquinavir  688.1 ± 11.3*** 32070 ± 1511*** 
 Naringin 332.3 ± 11.3▼ 14070 ± 598.2♦ 
Atazanavir  671.1 ± 8.4*** 28310 ± 1536*** 
 Naringin 312.8 ± 3.3● 11620 ± 1464ɵ 
For caspase-3 ***p < 0.0001 compared to controls, ͚ p < 0.0001 compared to nelfinavir, ▼ p < 0.0001 compared to 
saquinavir and ● p < 0.0001 compared to atazanavir respectively. RFU: Relative Fluorescence Units. For caspase-
9; ***p < 0.0001 compared to controls, ♠p < 0.0001 compared to nelfinavir, ♦p < 0.0001 compared to saquinavir 
and ɵp < 0.0001 compared to atazanavir respectively.  RLU : Relative Light Units 
 
                                                   
 
 










                                                      CHAPTER FOUR 
 
4.1 Discussion 
Chronic exposure to PIs has been linked with lipodystrophy, cardiovascular diseases, insulin 
resistance and type 2 diabetes (Heath et al., 2002; Souza et al., 2013; Vu et al., 2013). In the 
present study, we investigated whether PI-mediated β-cell dysfunction and insulin impairment 
is through increased oxidative stress and ATP depletion. In doing so, RIN-5F cells were exposed 
to different PIs (nelfinavir, saquinavir and atazanavir) and/ or glibenclamide (well-known 
antidiabetic drug used to increase insulin secretion in pancreatic β-cells) in the presence of 
varying glucose concentrations (11-25 mM), and assessed the effect of PIs on insulin secretion 
and oxidative stress. This study further investigated the putative protective antioxidant effects 
of naringin against oxidative stress induced by PIs (nelfinavir, saquinavir and atazanavir) on 11 
mM glucose concentration.  
 
Our results show that insulin secretion is glucose-dependent (Figure 10 A and B), demonstrating 
that pancreatic β-cells possessed normal features of glucose metabolism and insulin secretion 
(Patterson et al., 2014; Wallenius et al., 2002). Glucose is the primary regulator of insulin 
secretion in the pancreatic β-cells (Abudula et al., 2004; Guo et al., 2014; Meloni et al., 2013). 
The pancreatic β-cells sense an increased extracellular glucose and allow glucose to enter the 
cell via Glucose Transporter 2 (GLUT 2) (Guo et al., 2014; Meloni et al., 2013).  Glucose is 
then phosphorylated by glucokinase as leading to generation of pyruvate in the cytoplasm via 
glycolysis pathway (Remedi and Nichols, 2009). Pyruvate enters the mitochondrion and act as 
a substrate for pyruvate dehydrogenase and pyruvate carboxylase leading to generation of 
reducing equivalents NADH and FADH2 from Kreb cycle, which  then activates respiratory 
chain for ATP synthesis (Wollheim and Maechler, 2002). This process leads to increase 




intracellular ATP/ADP ratio thus triggering insulin secretion through the closure of K+ATP and 
open voltage-gated Ca2+ (Guo et al., 2014; Henquin, 2004; Wollheim and Maechler, 2002). 
Glibenclamide, a sulfonylurea receptor blocker, increased glucose-induced insulin secretion in 
the controls suggesting it role on enhancing insulin secretion (Luzi and Pozza, 1997; Patane et 
al., 2000).     
 
Consequently, ATP levels were increased in a glucose-dependent manner in RIN-5F cells treated 
with or without PIs and/or glibenclamide for 24 hr (Figure 11 A and B). These data support the 
fact that insulin secretion is dependent on ATP/ADP ratio which is a normal characteristic of 
the response of β-cells to glucose stimulation (Henquin, 2004; Maechler and Wollheim, 2001; 
Wollheim and Maechler, 2002). The K+ATP channel of pancreatic β-cell is composed of four 
pore-forming K+IR 6.2 subunits and the four controlling sulfonylurea receptor 1 (SUR1) 
together control pore permissibility (Henquin, 2004; Neye et al., 2006). The K+IR 6.2 subunit 
acts as a glucose/ATP sensor (Meloni et al., 2013). ATP binds to K+IR 6.2 closes the K+ATP 
channel, while binding of MgADP to SURI opens the channel (Henquin, 2004; Neye et al., 
2006). This results in depolarization of cell membrane, thus opening voltage-gated Ca2+ 
(Ashcroft and Rorsman, 2013; Dart, 2012; Henquin, 2004). This leads to increase in cytosolic 
Ca2+ concentration, which will then triggers insulin release via exocytosis (Ashcroft and 
Rorsman, 2013; Dart, 2012; Henquin, 2004; Vlacich et al., 2010). The findings of this study are 
similar to those of Gu et al., (2013) who investigated the effect of ginenosine compound K (a 
metabolite of protopanadiol ginsenosides) with regard to the expression of GLUT 2 and 
intracellular ATP concentration on MIN6 pancreatic β-cells and untreated controls exhibited 
higher levels of both insulin and ATP in response to 3 and 30 mM glucose. Similar results were 
also obtained by Moynihan et al., (2005) who demonstrated that SIRT1 (enzyme that 
deacetylates proteins to contribute to cellular regulation) improves insulin secretion in response 




to glucose and potassium chloride in β-cell-specific Sirt1-overexpressing transgenic mice. 
Moreover, Dufer et al (2004) evaluated the direct effect of HIV-PIs (ritonavir, nelfinavir and 
indinavir) with regards to stimulus-secretion coupling in β-cells. One of the observations in all 
treatments was an increased insulin secretion in response to 15 mM glucose compared to 3 mM. 
Therefore, these findings implied that RIN-5F cells used in this study retained their glucose-
induced insulin secretion capacity.  
 
However, treatment of RIN-5F cells with PIs (nelfinavir, saquinavir and atazanavir) led to 
reduced insulin levels in a glucose-dependent manner (Figure 10 A). This is thought to be as a 
result of decreased ATP concentrations due to increased production of ROS. It has been 
suggested that the ROS superoxide activates UCP-2, which promotes proton leakage, 
diminishing potential gradient and thus reducing ATP synthesis (Sakai et al., 2003). Depletion 
of ATP concentrations opens K+ATP, causing partial depolarization of cell membrane,   reduced 
cytosolic Ca2+ and therefore diminished insulin secretion. These findings correlated with those 
of Schutt et al., (2004) who found out that nelfinavir, saquinavir and ritonavir significantly 
impair glucose-stimulated insulin secretion accompanied by decrease in insulin-stimulated IRS-
1 and Th308-Akt phosphorylation effects.  Likewise, Koster et al., (2003) observed that insulin 
secretion from both MIN6 cell lines and rodent islets is significantly suppressed by indinavir 
with an IC50 of 1.1 and 2.1 µmol/l respectively. Therefore, our results are in agreement with 
other authors who report that PI treatment causes reduced insulin secretion in pancreatic β-cells. 
Linear regression analysis showed that decrease in insulin levels in response to nelfinavir (5-10 
µM), saquinavir (5-10 µM) and atazanavir (15-25 µM) is concentration-dependent (Figure 12). 
However, addition of glibenclamide to PIs significantly improved  insulin secretion in a glucose-
dependent manner, supporting its mechanism of action by binding K+ATP subunit sulfonylurea 




receptor 1, promoting cell membrane depolarization leading to increased Ca2+ influx therefore 
triggering insulin release by pancreatic β-cells (Figure 10 B).  
 
In support of this, our results show a decrease in ATP concentration in response to PI and glucose 
(Figure 11 A), which correlates with previous findings in where insulin secretion decreased upon 
PI exposure. These findings are supported by those of Chandra et al., (2009) who investigated 
the role of PI-mediated oxidative stress in inhibiting glucose-stimulated insulin release and 
reported decrease in ATP levels in INS-1cells after treatment with nelfinavir for 24 hr. 
Glibenclamide however, increased ATP production in a glucose-dependent manner (Figure 11 
B). This shows that glibenclamide increases insulin secretion which has anabolic effects on the 
β-cells by up-regulating antioxidant synthesis (Erejuwa et al., 2010; 2011).    
 
This study further explored whether PI-mediated impairment of insulin secretion is through the 
increase oxidative stress. Oxidative stress is well-known to induce inflammation, 
atherosclerosis, cancer, diabetes mellitus, neurodegenerative diseases and cardiovascular 
disease (Sreelatha and Padma, 2011). Reactive oxygen species are enhanced to oxidize 
phospholipids membranes consequently leading to lipid peroxidation (Sreelatha and Padma, 
2011). Polyunsaturated fatty acids (PUFAs) are mostly vulnerable to peroxidation because of 
the presence of double bonds between methylene-carbon (CH2) and the reactive hydrogen (H) 
atom (Halliwell and Chirico, 1993). The chain reaction is initiated when free radicals react with 
hydrogen atoms and obstruct them from PUFAs, resulting in the formation of carbon –centered 
lipid radicals (Halliwell and Chirico, 1993). Lipid radicals are not stable, therefore, they reacts 
with oxygen (O2) and form peroxyl radicals and hydroperoxides (Halliwell and Chirico, 1993). 
Peroxyl radicals are then reduced to form reactive aldehydes including malondialdehyde (MDA) 
and isoprostanes as by-products (Halliwell and Chirico, 1993). In this regard, our results showed 




that PIs significantly increased lipid peroxidation as assessed by elevated MDA concentrations 
in a glucose-dependent manner (Figure 13 A). The RIN-5F cells treated with atazanavir had 
significantly elevated MDA concentrations compared to the controls and were also significantly 
lower compared to nelfinavir and saquinavir at 25 mM glucose. This implies that atazanavir 
produces lesser free radicals compared to both nelfinavir and saquinavir, postulating that 
atazanavir had lesser effects on coupling oxidative phosphorylation for ATP generation. 
Previous studies by Ben-Romano et al., (2006) have reported that nelfinavir and saquinavir are 
strongly linked with cytotoxicity in  patients based on PI-therapy compared to other PIs  (Kraus 
et al., 2013). Therefore, this finding shows that atazanavir is less likely to induce cytotoxicity 
compared to nelfinavir and saquinavir.  Glibenclamide however, reversed MDA concentrations 
suggesting a role of glibenclamide in relieving oxidative stress therefore buffering the cells from 
oxidative damage (Figure 13 B). In addition, lipid peroxidation is known to compromise cell 
membranes including mitochondrial membranes which become dysfunctional (Kim et al., 2009; 
Sreelatha and Padma, 2011). Due to these actions, uncoupling of oxidative phosphorylation 
occurs, leading to increased electron leakage from the ETC and subsequent reduction of ATP 
production (Chandra et al., 2009; Produit-Zengaffinen et al., 2007).  In several cell lines such as 
human myotubes, rat insulinoma cell line or vascular smooth cells, PIs have been found to 
induce production of ROS that is inhibited by co-exposure with the antioxidants resveratrol (Kim 
et al., 2009) or thymoquinone (Chandra et al., 2009) or N-acetyl cysteine (Ben-Romano et al., 
2006). In the rat pancreatic insulinoma cells, a direct role of ROS in the inhibition of insulin 
secretion by nelfinavir is suggested because thymoquinone (a constituent of black seed oil 
possessed antioxidant properties) reverses the suppressive effect of nelfinavir (Chandra et al., 
2009).  
 




Superoxide is produced through the transfer of electron to oxygen molecule, and then converted 
to hydrogen peroxide and oxygen molecule by mitochondrial superoxide dismutase (Lenaz, 
2001; Turrens, 2003). This study showed an increase in SOD activity in response to PI and 
glucose in a glucose dependent manner (Figure 14 A), suggesting that SOD react to 
accommodate excess free radicals produced. The SOD enzymes catalyses the dismutation of 
superoxide anion into hydrogen peroxides and oxygen molecule thus reduces the cytotoxicity 
(Murphy, 2009; Turrens, 2003). Glutathione scavenges hydrogen peroxide, peroxynitrite, 
hydroperoxides and fatty acid peroxyl radicals (Chapple et al., 2002; Marí et al., 2009). 
Glutathione peroxidase and glutathione-S-transferase (GST) enzymes catalyse GSH-mediated 
detoxification of electrophilic species (Chapple et al., 2002; Marí et al., 2009). Glutathione acts 
as an electron donor in a reduction reaction catalysed by GPx to detoxify peroxides (Chapple et 
al., 2002; Marí et al., 2009). This study shows reduced GSH levels in a glucose dependent 
manner but initially increased in cells that were exposed to PIs (Figure 15 A). This suggests that 
the combined assault of PIs and hyperglycemia initially induced antioxidant effects (by increase 
ROS generation) which got depleted as glucose concentrations increased. These findings are 
similar to those of Chandra et al., (2009) who showed the decrease insulin secretion in INS-1 
cells at different concentrations of PIs (nelfinavir 5-10 µM; saquinavir 5-10 µM and atazanavir 
8-20 µM) after 24 h exposure, and the treatments demonstrated the increase ROS generation and 
UCP2 expression, decrease GSH and ATP levels. Glibenclamide however, sustained GSH 
cellular content suggesting the anabolic effects of insulin which increased synthesis of inducible 
GSH (Figure 15 B). Altogether, our data suggests that PIs could be generating ROS which 
uncouple oxidative phosphorylation in the mitochondria leading to decreased inhibition of KATP 
pump and subsequent reduction of insulin secretion.  
 




Excessive production of mitochondrial ROS and oxidation of mitochondrial pores lead to 
apoptosis (Kanno et al., 2003; Sreelatha and Padma, 2011). This stimulus for apoptosis is 
through the activation of Bax, a pro-apoptotic protein, which causes mitochondrial 
permeabilisation and the release of cytochrome C release into the mitochondrial cytoplasm 
(Mishra and Kumar, 2005; Park and Han, 2014). This results in the formation of apoptosome 
with cytochrome c, Apaf-1 and procaspase-9 (Mishra and Kumar, 2005; Park and Han, 2014). 
The oligomerisation of procaspase-9 in apoptosome formed results in the activation of caspase-
9 which in turn activates caspase-3 (Mishra and Kumar, 2005; Park and Han, 2014). Activated 
caspase-3 leads to cell death characterized by chromatin condensation, nuclear fragmentation, 
DNA ladder and formation of apoptotic bodies (Mishra and Kumar, 2005; Park and Han, 2014). 
Our findings showed that PIs significantly up-regulated the activities of both caspases-3 and -9 
in a glucose-dependent manner (Table 2 and 3), suggesting that RIN-5F cells undergo apoptosis 
after 24 h exposure to PIs and glucose. Glibenclamide however, reversed activities of both 
caspase-3 and -9 in a glucose-dependent manner. Correspondingly, Zang et al., (2009) reported 
the insulinopenia in Zucker fa/fa rats treated with PI (indinavir) for 7 weeks, suggesting chronic 
exposure to PI to induce β-cell dysfunction. The study was supported by increased apoptosis 
and reduced insulin secretion in rat insulinoma cells and human pancreatic β-cells treated with 
ritonavir, lopinavir, atazanavir or tipranavir for 48-96 h. In addition to study by Zang et al., 
(2009), chronic exposure to PIs triggers mitochondrial-associated caspase-9, causing the loss of 
membrane potential and promote the release of cytochrome c. In this regard, HIV-PIs induce β-
cell apoptosis by triggering mitochondrial apoptosis pathway. Therefore, this study postulates 
that PIs impaired insulin secretion by pancreatic β-cells through increasing oxidative stress that 
leads to cellular damage.  
 




Dysfunction of pancreatic β-cells is known to play a crucial role in the pathogenesis of diabetic 
type 2 and insulin resistance (Prentki et al., 2002; Unger, 1995). To decrease the risk of such 
pathological damage, it is therefore important to find the interventions that will prevent the 
oxidative stress and apoptosis induced by PIs so that patients acquire better prognosis. This study 
explored the antioxidant properties of naringin, a plant derived flavonone using 11 mM glucose 
concentration on RIN-5F cells exposed to different PIs; nelfinavir, saquinavir and atazanavir for 
24 h. Our findings supported the beneficial effects of naringin on the PI-induced cytotoxicity. 
This effect of naringin is associated with its antioxidant properties, because it is postulated to 
have inhibited PI-induced oxidative stress. Our data show that naringin treatment exhibited a 
dose-dependent increase in insulin secretion (r2 = 0.9589) in RIN-5F cells (Figure 16). These 
finding correlates with those of Ali et al (2004) who demonstrated that exogenous administration 
of several doses of naringin to streptozotocin-induced hyperglycemia showed decrease glucose 
concentration and increased insulin secretion. Addition of naringin to PIs (nelfinavir, saquinavir 
and atazanavir) significantly suppressed (p < 0.0001) PI-induced oxidative stress (Figure 17) 
and protected SOD expression in PIs exposure (Figure 18), suggesting the potential role of 
naringin as a free oxygen radical scavenger. This data is supported by previous evidence that 
co-treatment of naringin together with PI significantly increased (p < 0.0001) intracellular GSH 
(Figure 19) and ATP production (Figure 20), implying that naringin protect the RIN-5F cells 
from oxidative damage and promoting insulin secretion evidenced by increased ATP/ADP ratio. 
According to Amudha and Pari (2011) naringin exerts its antioxidant effects by up-regulating 
gene expression of SOD and GPx with subsequently scavenge ROS. Cavia-Saiz et al., (2010) 
postulated that the presence of hydrogen donating substituents attached to aromatic rings could 
enable naringin to scavenge oxidant species. Taken together, naringin treatment improved 
secretory responsiveness in β-cells at 11 mM glucose conditions and the mechanisms may be 




involved in the protection of insulin secreting cells by reducing oxidative stress and increasing 
cell function.  
 
This study further observed that naringin protect RIN-5F cells against PI-induced apoptosis. The 
antiapoptotic effects of naringin was due to the decrease activity of caspase-3 and -9 (Table 4) 
against PI-induce cellular damage and linked to its antioxidant potential.  Our results are similar 
to previous studies that suggested to naringin have mitochondrial protectiveness against 
activation of caspase-3 and -9; it decreases expression of Bax, p53 protein and cleavages of 
caspase-3, and increases expression of Bcl2 (Sahu et al., 2014). Hak-Jae at al., (2009) 
demonstrated that naringin prevented rotenone-induced phosphorylation of JNK and p38; 
therefore preventing changes in Bcl2 and associated with Bax expression levels in human SH-
SY5Y cells. In addition, Hak-Jae et al., (2009) further provided more evidence with regards to 
decrease in apoptosis by naringin in human SH-SY5Y cells by it preventing cleavages of 
caspase-9, poly (ADP-ribose) polymerase (PARP; a biochemical hallmark of apoptosis) and 
caspase-3 and decrease enzyme activity of caspase-3. Consequently Chen et al., (2014), 
demonstrated that naringin protects cardiac H9c2 cells-induced hyperglycemia from apoptosis 
by inhibiting stimulation of MAPK, especially JNK, ERK1/2 and p38 MAPK.  C-Jun NH2 
terminal kinase is known to release apoptogenic factors cytochrome c and smac/DIABLO to 
initiate apoptosis whereas p38 MAPK is involved in the phosphorylation of Bcl2 and triggering 
mitochondrial apoptotic pathway (Chen et al., 2014). Our data clearly suggest that naringin 
prevent apoptosis in RIN-5F cells under 11 mM glucose concentration and the mechanisms 
involved may be though reduction of oxidative stress that is known to induce cell death, 
therefore increasing cell survival.   
 
 




                                                      CHAPTER FIVE 
5.0 Conclusions 
Metabolic syndrome in HIV patients receiving PI-based therapy has been becomes a major 
concern worldwide. Protease inhibitors (PIs) were shown to induce β-cell dysfunction and 
impair insulin secretion by increasing oxidative stress and ATP depletion. Dysfunction or 
reduced numbers of pancreatic β-cells are the influential factors in the development of type 2 
diabetes and insulin resistance. Therefore, this emphasizes the need for the development of 
cheap and safer therapies such a naturally occurring flavonone, naringin to improve longevity 
brought by antiretroviral regimen.  
  
Our data showed that HIV-PIs inhibit glucose-induce insulin secretion in pancreatic β-cells. The 
effect is mediated through increased oxidative stress, decrease ATP and antioxidant (GSH) 
mechanisms. Moreover, our study showed that naringin ameliorated PIs-induced impairment of 
β-cell dysfunction at 11 mM glucose concentration by reducing oxidative stress and preserved 
pancreatic β-cell integrity. These findings therefore suggest that naringin may be considered as 
a therapeutic agent in the management of PI-associated metabolic syndrome with respect to 
pancreatic β-cell dysfunction.  
 
However, it is recommended that the role of naringin at different concentrations of HIV-PIs as 
well as of glucose should be considered in further/subsequent studies. The cytological analysis 
of the cultured cells under various concentrations of HIV-PIs/ naringin should be done to 
ascertain if there are any mitochondrial structural changes. Concentration levels of Ca2+ ions 
should be determined at various HIV-PIs/ naringin treatment levels. Lastly, the expression of 
uncoupling protein 2 should be determined at various HIV/PIs/ naringin concentration levels.   
 




Furthermore, this study recommends that studies be carried out to ascertain the effects of 
naringin in vivo and isolated pancreatic β-cells with respect to oxidative stress, anti-oxidant 
capacity, insulin secretion and apoptosis. This study also recommends that studies be carried out 
to ascertain the effects of naringin in different pancreatic β-cell lines in a glucose dependent 
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 Insulin ELISA 
Table A and B: Glucose-induced insulin secretion in cells that were treated with (A) PIs 











































































Table A and B: ATP productions after cells were treated with (A) PIs and/or (B) 













162.212 166.030 156.483 
262.120 266.549 244.756 
508.100 515.230 512.115 
809.100 789.036 816.450 
 
 
40.05 37.924 39.261 
80.123 64.810 80.421 
109.134 151.089 116.101 
220.128 225.059 225.056 
 
 
47.661 26.469 41.170 
70.513 59.820 75.010 
108.165 121.175 117.641 
216.561 205.456 213.075 
 
49.570 47.852 42.125 
90.540 88.615 84.125 
151.089 161.176 121.195 

















280.011  279.890  285.001 
405.962 415.040 409.222 
650.786 659.165 647.952 
865.984 871.614 889.001 
 
 
108.755 118.165 103.392 
148.046 144.258 180.409 
405.153 418.222 416.236 
606.498 616.579 610.956 
 
 
105.028 89.119 109.209 
133.831 158.019 166.963 
390.450 385.162 365.124 
589.563 572.146 601.000 
 
 
101.665 118.574 97.847 
184.650 175.280 165.684 
415.365 416.023 420.125 












Linear regression analysis of concentration-depend inhibition of insulin secretion in RIN-
































    
0.9048414 1.155237 























Table A and B: TBARS assay measured as MDA concentrations after cells were treated 













0.025 0.023 0.023 
0.030 0.033 0.041 
0.765 0.780 1.090 
2.580 2.660 2.590 
 
0.278 0.380 0.378 
0.340 0.360 0.360 
1.020 1.085 1.090 
3.390 3.411 3.421 
 
0.358  0.373 0.283 
0.389 0.375 0.315 
1.163 
   
1.129 0.950 
3.401 3.375 3.391 
 
0.275 0.260 0.262 
0.310 0.314 0.320 
0.932 0.940 0.960 

















0.0250 0.0210 0.0190 
0.0220 0.0350 0.0260 
0.0310 0.0350 0.0290 
0.0290 0.0400 0.0330 
 
0.106 0.072 0.090 
0.206 0.144 0.188 
0.616 0.432 0.564 
2.550 2.720 2.701 
 
0.072 0.075 0.084 
0.144 0.140 0.165 
0.430 0.440 0.506 
2.270 2.760 2.280 
 
0.040 0.065 0.055 
0.080 0.135 0.110 
0.428 0.436 0.425 









Table A and B: SOD activity after cells were exposed with (A) PIs and/or (B) 













0.048 0.040 0.056 
0.096 0.090 0.110 
0.288 0.276 0.330 
1.864 1.810 1.790 
 
0.115 0.109 0.110 
0.230 0.228 0.220 
0.690 0.680 0.664 
2.070 2.052 1.980 
 
0.158 0.130 0.128 
0.316 0.270 0.256 
0.715 0.720 0.723 
2.130 2.160 2.175 
 
0.108 0.112 0.100 
0.226 0.235 0.265 
0.678 0.716 0.700 
















0.098 0.102 0.101 
0.204 0.201 0.198 
0.615 0.613 0.598 
1.861 1.761 1.858 
 
0.077 0.055 0.055 
0.140 0.125 0.130 
0.423 0.375 0.395 
1.160 1.075 1.090 
 
0.065 0.053 0.049 
0.130 0.106 0.098 
0.390 0.382 0.285 
1.170 0.989 0.885 
 
0.070 0.040 0.041 
0.140 0.160 0.168 
0.387 0.401 0.419 












Glutathione (GSH) assay 
Table A and B: Glutathione levels after cells were exposed with (A) PIs and/or (B) 













9501.00 9616.12 8896.36 
7818.00 7734.01 7832.12 
5252.13 5193.43 5908.61 
994.69 999.05 1094.66 
 
210.45 1281.59 1381.99 
4227.74 4112.84 4051.52 
 3182.41 3161.14 3160.63 
718.00 734.01 732.12 
 
1152.4 1071.1 1159.6 
4085.9 3763.4 4001.8 
3159.0 3152.6 2999.6 
740.55 682.45  702.59 
 
1538.23 1420.92 1454.55 
4365.24 4296.62 4458.90 
3452.00 3600.29 3650.36 
















6685.0 6714.00 6710.00 
8250.00 8189.00 8231.00 
8031.00 7961.00 7750.00 
8582.41 8614.14 8602.63 
 
5571.19 5588.96 5616.94 
7195.27 7006.04 7370.71 
5494.08 5388.11 5500.36 
5114.94 5244.05 5172.80 
 
5741.05 5770.80 5721.64 
6875.79 7270.28 7264.55 
5652.24 5640.90 5335.85 
4999.40 5067.84 5201.26 
 
 
5411.14   
          
5483.43      5381.401 
5869.82 
       
6954.81      6765.519 
6064.94   6119.64      6203.210 
5275.23 5299.27      5281.660 











Caspase -3 assay                                         
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Figure 1: Caspase -3 activities in RIN-5F cells treated with PIs and glibenclamide (A/B) s for 
24 h at 11-15 mM glucose concentration 
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Figure 2: Caspase -9 activities in RIN-5F cells treated with PIs and/ glibenclamide (A/B) for 









Table1: A dose-dependent increase insulin secretion in cells after naringin treatment for 
24 h at 11 mM glucose.     
   Naringin 
       (µM) 
Insulin levels     
(µg/L) 
          0.0 
         10.0 
         20.0 
         30.0 
         40.0 
         50.0 
     1.0670 
     1.1845 
     1.6220 
     1.6920 
     1.9180 




Table 2:  Malondialdehyde (lipid peroxidation) levels in RIN-5F cells treated with PIs 
and/ or naringin for 24 h at mM glucose concentration. 












































Table 3: SOD activity after cells were exposed to PIs and/ or naringin for 24 hours at 
11mM glucose concentration.  


































Table 4: Glutathione levels after cells were exposed to PIs and/naringin for 24 hours at 
11 mM glucose concentration. 



































Table 5: ATP levels after cells were exposed to PIs and/ or naringin for 24 h at 11 Mm 
glucose concentration. 














































































































Figure 3: Caspase-9 activities in RIN-5F cells treated with PIs and naringin for 24 h at 11 mM 








































































Figure 4: Caspase-3 activities in RIN-5F cells treated with PIs and naringin for 24 h at 11 mM 
glucose concentration.   
 
